Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Thorac Oncol
    April 2024
  1. ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
    Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
    >> Share

  2. HORNE A, Harada K, Brown KD, Chua KLM, et al
    Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
    >> Share

  3. KIM IH, Lee GD, Choi S, Kim HR, et al
    Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
    >> Share

  4. SHUKLA V, Wang H, Varticovski L, Baek S, et al
    Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
    >> Share

  5. DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
    >> Share

  6. CHANG CL, Lin KC, Chen WM, Shia BC, et al
    Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e2-e4.
    >> Share

  7. CHIOU CC, Lai TY
    Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e1-e2.
    >> Share

  8. SMESSEIM I, Baas P
    Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
    J Thorac Oncol. 2024;19:547-550.
    >> Share

  9. GRAY SG, Meirson T, Mutti L
    Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
    J Thorac Oncol. 2024;19:541-546.
    >> Share

  10. SAIFO M, Alali M, Alhabeb H, Awak M, et al
    Lung Cancer in Syria.
    J Thorac Oncol. 2024;19:534-540.
    >> Share

  11. SHOENBILL KA, Goldstein AO
    Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
    J Thorac Oncol. 2024;19:531-533.
    >> Share

  12. ZHU Z, Chen H
    Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
    J Thorac Oncol. 2024;19:528-530.
    >> Share

  13. LEE JB, Nagasaka M
    Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
    J Thorac Oncol. 2024;19:525-527.
    >> Share

  14. LEONG TL, McWilliams A, Wright GM
    Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
    J Thorac Oncol. 2024;19:522-524.
    >> Share

  15. DWYER LJ, Singhal N, Yu B, Kao S, et al
    Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
    J Thorac Oncol. 2024;19:650-652.
    >> Share

  16. RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
    Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
    J Thorac Oncol. 2024;19:626-635.
    >> Share

  17. MCNAMEE N, Harvey C, Gray L, Khoo T, et al
    Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
    J Thorac Oncol. 2024;19:636-642.
    >> Share

  18. NEL AE, Pavlisko EN, Roggli VL
    The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
    J Thorac Oncol. 2024;19:551-564.
    >> Share

    March 2024
  19. TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
    The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
    J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
    >> Share

  20. BORGEAUD M, Parikh K, Banna GL, Kim F, et al
    Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
    J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
    >> Share

  21. HINES JB, Cameron RB, Esposito A, Kim L, et al
    Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
    J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
    >> Share

  22. CHENG Y, Fan Y, Zhao Y, Huang D, et al
    Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
    J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
    >> Share

  23. RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
    >> Share

  24. KIM BG, Yoon S, Lee SY, Sohn JW, et al
    How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
    J Thorac Oncol. 2024;19:509-510.
    >> Share

  25. WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
    Lung Cancer in Switzerland.
    J Thorac Oncol. 2024;19:385-394.
    >> Share

  26. TEN HAAF K
    Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
    J Thorac Oncol. 2024;19:373-375.
    >> Share

  27. LI CP, Tsai RY, Chang HC, Gau SY, et al
    Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:507-508.
    >> Share

  28. CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
    Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2024;19:380-384.
    >> Share

  29. LIM SM, Lee JB, Cho BC
    Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2024;19:376-379.
    >> Share

  30. YALAMANCHALI A, Hassan KA
    MUC1-C: The Occam Razor of Osimertinib Resistance?
    J Thorac Oncol. 2024;19:370-372.
    >> Share

  31. DAMMEIJER F, Dumoulin DW, Aerts JGJV
    Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
    J Thorac Oncol. 2024;19:366-369.
    >> Share

  32. CANI M, Novello S, Bironzo P
    Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
    J Thorac Oncol. 2024;19:363-365.
    >> Share

  33. BORCZUK AC
    Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
    J Thorac Oncol. 2024;19:360-362.
    >> Share

  34. YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
    Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
    J Thorac Oncol. 2024;19:409-424.
    >> Share

    February 2024
  35. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
    >> Share

  36. ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
    Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
    >> Share

  37. TORASAWA M, Horinouchi H
    A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
    J Thorac Oncol. 2024;19:351-352.
    >> Share

  38. NISHIMURA T
    A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
    J Thorac Oncol. 2024;19:350.
    >> Share

  39. HORITA N, Takase-Minegishi K
    Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
    J Thorac Oncol. 2024;19:348.
    >> Share

  40. CHANG HC, Gau SY
    Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:346.
    >> Share

  41. YUAN C, Huang R, Wang Y
    An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
    J Thorac Oncol. 2024;19:344-345.
    >> Share

  42. BERMAS BL, Gerber DE
    The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:196-198.
    >> Share

  43. VOKES EE, Mornex F, Sezer A, Cheng Y, et al
    Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
    J Thorac Oncol. 2024;19:285-296.
    >> Share

  44. REMON J, Saw SPL, Cortiula F, Singh PK, et al
    Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
    J Thorac Oncol. 2024;19:199-215.
    >> Share

  45. DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
    Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
    J Thorac Oncol. 2024;19:273-284.
    >> Share

  46. OWONIKOKO TK
    SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
    J Thorac Oncol. 2024;19:193-195.
    >> Share

  47. LE X
    Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:190-192.
    >> Share

  48. LEE JH
    Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
    J Thorac Oncol. 2024;19:187-189.
    >> Share

  49. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
    Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
    J Thorac Oncol. 2024;19:337-343.
    >> Share

    January 2024
  50. SHI Y, Hu X, Li X, Gong C, et al
    Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
    J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
    >> Share

  51. SHI Y, Chen J, Yang R, Wu H, et al
    Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
    J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
    >> Share

  52. NASSAR AH, Kim SY, Aredo JV, Feng J, et al
    Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
    J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
    >> Share

  53. SIMONS E, Camidge DR
    Lung cancer oncogene-directed therapy, fertility and pregnancy.
    J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
    >> Share

  54. YU S, Feng J
    Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
    J Thorac Oncol. 2024;19:173-174.
    >> Share

  55. TANIZAKI J, Hayashi H
    Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
    J Thorac Oncol. 2024;19:15-17.
    >> Share

  56. BATAH H, Majeed Z, Moudgil R
    Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
    J Thorac Oncol. 2024;19:13-14.
    >> Share

  57. SINGHAL S, Gandara D, Riess JW
    Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
    J Thorac Oncol. 2024;19:10-12.
    >> Share

  58. FANG W, Girard N, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2024;19:52-70.
    >> Share

  59. CHEN MF, Harada G, Liu D, DeMatteo R, et al
    Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
    J Thorac Oncol. 2024;19:153-159.
    >> Share

  60. UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
    HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    J Thorac Oncol. 2024;19:106-118.
    >> Share

  61. HAMADA A, Suda K, Nishino M, Obata K, et al
    Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
    J Thorac Oncol. 2024;19:71-79.
    >> Share

  62. LAM S, Wynes MW, Connolly C, Ashizawa K, et al
    The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
    J Thorac Oncol. 2024;19:94-105.
    >> Share

  63. TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
    Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:166-172.
    >> Share

    December 2023
  64. YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
    Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
    J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
    >> Share

  65. ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
    Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
    >> Share

  66. BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
    Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
    J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
    >> Share

  67. VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
    >> Share

  68. LI W, Fei K, Guo L, Wang Y, et al
    CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
    >> Share

  69. DACIC S, Travis WD, Giltnane JM, Kos F, et al
    Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
    >> Share

  70. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
    Lung Cancer in Albania.
    J Thorac Oncol. 2023;18:1632-1637.
    >> Share

  71. FERREIRA M, Redman MW, Reckamp KL
    Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
    J Thorac Oncol. 2023;18:1629-1631.
    >> Share

  72. LI Z, Lu S
    Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
    J Thorac Oncol. 2023;18:1625-1628.
    >> Share

  73. MAKAREM M, Rotow JK
    Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    J Thorac Oncol. 2023;18:1615-1617.
    >> Share

  74. RUFFINI E, Huang J, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1655-1671.
    >> Share

  75. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
    J Thorac Oncol. 2023;18:1672-1688.
    >> Share

  76. OKUMURA M, Marino M, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1638-1654.
    >> Share

  77. ANG YLE, Soo RA
    Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
    J Thorac Oncol. 2023;18:1621-1624.
    >> Share

  78. MEDINA CG, Xu Y, Ripley RT
    International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
    J Thorac Oncol. 2023;18:1618-1620.
    >> Share

  79. SOO RA, Cho BC, Kim JH, Ahn MJ, et al
    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
    J Thorac Oncol. 2023;18:1756-1766.
    >> Share

  80. WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
    J Thorac Oncol. 2023;18:1689-1702.
    >> Share

    November 2023
  81. WANG K, Du R, Myall NJ, Lewis WE, et al
    BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
    >> Share

  82. O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
    Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
    >> Share

  83. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
    Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
    J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
    >> Share

  84. LU C, Wei XW, Wang Z, Zhou Z, et al
    Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
    J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
    >> Share

  85. HENSCHKE C, Huber R, Jiang L, Yang D, et al
    Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
    J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
    >> Share

  86. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
    Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
    >> Share

  87. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
    No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
    >> Share

  88. YANG JJ, Wen W, Zahed H, Zheng W, et al
    Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
    J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
    >> Share

  89. KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
    Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
    >> Share

  90. HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
    MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
    >> Share

  91. HONG TH, Hwang S, Cho J, Choi YL, et al
    Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
    >> Share

  92. QIU Z, Huang H, Zhang Y, Chen D, et al
    Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
    J Thorac Oncol. 2023;18:e138-e139.
    >> Share

  93. LI A, Yang Y, Zhang L, Hong S, et al
    STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
    J Thorac Oncol. 2023;18:e135-e138.
    >> Share

  94. AMORI G, Sugawara E, Inamura K
    Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
    J Thorac Oncol. 2023;18:e134-e135.
    >> Share

  95. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e132-e134.
    >> Share

  96. ZHANG Y, Dai K, He D, Chen Z, et al
    The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e130-e131.
    >> Share

  97. NIU Y, Yao F, Yang H
    "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
    J Thorac Oncol. 2023;18:e126-e128.
    >> Share

  98. MARTI JLG, Wells JZ, Wells A
    Statins as a Secondary Preventive Agent for Metastatic Cancer.
    J Thorac Oncol. 2023;18:e125-e126.
    >> Share

  99. OKONTA KE, Baiyewu LA, Jimoh MA
    Lung Cancer in Nigeria.
    J Thorac Oncol. 2023;18:1446-1457.
    >> Share

  100. DAGOGO-JACK I
    We Don't Talk (Enough) About BRAF.
    J Thorac Oncol. 2023;18:1443-1445.
    >> Share

  101. LEE JB, Ou SI
    Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
    J Thorac Oncol. 2023;18:1434-1442.
    >> Share

  102. HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
    A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    J Thorac Oncol. 2023;18:1431-1433.
    >> Share

  103. SOZZI G, Pastorino U
    Small RNAs Do It Better.
    J Thorac Oncol. 2023;18:1428-1430.
    >> Share

  104. YANKELEVITZ DF, Yip R, Henschke CI
    Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
    J Thorac Oncol. 2023;18:1426-1427.
    >> Share

  105. SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
    Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
    J Thorac Oncol. 2023;18:1538-1549.
    >> Share

  106. AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
    Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
    J Thorac Oncol. 2023;18:1594-1606.
    >> Share

    October 2023
  107. WANG L, Luo Y, Ren S, Zhang Z, et al
    A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
    J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
    >> Share

  108. HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
    >> Share

  109. CHO MH, Cho JH, Eun Y, Han K, et al
    Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
    J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
    >> Share

  110. STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
    >> Share

  111. HENSCHKE CI, Yip R, Sun Q, Li P, et al
    Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
    >> Share

  112. ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
    Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
    >> Share

  113. TRIPHURIDET N, Gao Y, Ou SI
    Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
    J Thorac Oncol. 2023;18:e122-e123.
    >> Share

  114. JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
    Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
    J Thorac Oncol. 2023;18:e118-e122.
    >> Share

  115. CHOUR A, Duruisseaux M
    Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
    J Thorac Oncol. 2023;18:e114-e115.
    >> Share

  116. DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
    The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
    J Thorac Oncol. 2023;18:1258-1260.
    >> Share

  117. INAMURA K
    Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
    J Thorac Oncol. 2023;18:e109-e110.
    >> Share

  118. ADJEI AA
    The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
    J Thorac Oncol. 2023;18:1257.
    >> Share

  119. HOE HJ, Balasubramanian A, John T
    LASERing FLAURAL Arrangements in Asian EGFR Subsets.
    J Thorac Oncol. 2023;18:1261-1264.
    >> Share

  120. REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
    Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
    J Thorac Oncol. 2023;18:1351-1361.
    >> Share

  121. PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
    Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
    J Thorac Oncol. 2023;18:1362-1385.
    >> Share

  122. GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
    Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
    J Thorac Oncol. 2023;18:e112-e113.
    >> Share

  123. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
    J Thorac Oncol. 2023;18:e107-e109.
    >> Share

  124. LIN TA, Chen SY, Chang R, Sun CK, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    J Thorac Oncol. 2023;18:e105-e106.
    >> Share

  125. WRIGHT K, Digby GC, Gyawali B, Jad R, et al
    Malignant Superior Vena Cava Syndrome: A Scoping Review.
    J Thorac Oncol. 2023;18:1268-1276.
    >> Share

    September 2023
  126. DUAN J, Wu L, Yang K, Zhao J, et al
    Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
    J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
    >> Share

  127. RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
    Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
    >> Share

  128. JIANG C, Zhang Y, Fu F, Deng P, et al
    A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
    >> Share

  129. TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
    Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
    >> Share

  130. WANG X, Bai H, Zhang J, Wang Z, et al
    Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
    >> Share

  131. FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
    Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
    >> Share

  132. ZHANG S, Liu L, Shi S, He H, et al
    Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
    J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
    >> Share

  133. DINGEMANS AC, Mathijssen RHJ, van Rossum EFC
    Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Non-Small Lung Cancer.
    J Thorac Oncol. 2023;18:e99-e100.
    >> Share

  134. LEE ATM, Ou SI, Lisberg A
    Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?
    J Thorac Oncol. 2023;18:e97-e99.
    >> Share

  135. GARCIA-PARDO M, Liu G
    Re: Response to Letter to the Editor "Respiratory and Cardiometabolic Comorbidities and Stage I-III Non-Small Cell Lung Cancer (NSCLC) Survival: A Pooled Analysis From the International Lung Cancer Consortium".
    J Thorac Oncol. 2023;18:e96-e97.
    >> Share

  136. ZHANG Y, Zhang J
    Comment on "Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium".
    J Thorac Oncol. 2023;18:e95-e96.
    >> Share

  137. FUJITA T, Amano H, Nakamura M, Hirano S, et al
    Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.
    J Thorac Oncol. 2023;18:e93-e94.
    >> Share

  138. PONVILAWAN B, Sharma P, Mahadevia H, Subramanian J, et al
    Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials.
    J Thorac Oncol. 2023;18:e90-e93.
    >> Share

  139. HONG TH, Bang YH, Joe C, Choi YL, et al
    Comment on "Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond".
    J Thorac Oncol. 2023;18:e88-e90.
    >> Share

  140. INAMURA K
    Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond.
    J Thorac Oncol. 2023;18:e87-e88.
    >> Share

  141. PAZ-ARES LG, Carbone DP
    Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".
    J Thorac Oncol. 2023;18:e102-e103.
    >> Share

  142. ZHAO B, Ma W
    First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA.
    J Thorac Oncol. 2023;18:e101-e102.
    >> Share

  143. ASMARA OD, Tenda ED, Singh G, Pitoyo CW, et al
    Lung Cancer in Indonesia.
    J Thorac Oncol. 2023;18:1134-1145.
    >> Share

  144. MOGHANAKI D, Lisberg A, Oh S, Lee JM, et al
    Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection.
    J Thorac Oncol. 2023;18:1129-1133.
    >> Share

  145. DICKHOFF C, Heineman DJ, Bahce I, Senan S, et al
    Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment.
    J Thorac Oncol. 2023;18:1124-1128.
    >> Share

  146. DENIZE T, Mino-Kenudson M
    "Normal" Is Not Normal: The Role of the Immune Microenvironment of Adjacent Non-Neoplastic Tissue in Dictating the Biology of Early-Stage NSCLC.
    J Thorac Oncol. 2023;18:1121-1123.
    >> Share

  147. FACCHINETTI F, Janne PA, Tiseo M
    Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era.
    J Thorac Oncol. 2023;18:1118-1120.
    >> Share

  148. SCHROEDER BA, Thomas A
    SCLC Subtypes and Biomarkers of the Transformative Immunotherapy Responses.
    J Thorac Oncol. 2023;18:1114-1117.
    >> Share

  149. CORNO C, Beretta GL, Perego P
    Concomitant Targeting of MDM2 and MEK: A New Translatable Combinatorial Strategy?
    J Thorac Oncol. 2023;18:1111-1113.
    >> Share

  150. OPITZ I, Bille A, Dafni U, Nackaerts K, et al
    European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
    J Thorac Oncol. 2023;18:1233-1247.
    >> Share

  151. FARINEA G, Crespi V, Listi A, Righi L, et al
    The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
    J Thorac Oncol. 2023;18:1146-1164.
    >> Share

  152. ELKRIEF A, Odintsov I, Markov V, Caeser R, et al
    Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    J Thorac Oncol. 2023;18:1165-1183.
    >> Share

    August 2023
  153. CHO BC, Lee JS, Wu YL, Cicin I, et al
    Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
    J Thorac Oncol. 2023 Aug 17:S1556-0864(23)00738.
    >> Share

  154. IMBODY D, Arce K, Solanki HS, Haura EB, et al
    Targeting SHP2 Signaling in Lung Cancer.
    J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00729.
    >> Share

  155. LI Y, Juergens RA, Finley C, Swaminath A, et al
    Moving Through Inertia - The Promise of Current and Future Treatment Options in the Management of Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00731.
    >> Share

  156. CHIH-HSIN YANG J, Liu G, Lu S, He J, et al
    Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
    J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00730.
    >> Share

  157. LARA-MEJIA L, Cardona AF, Mas L, Martin C, et al
    Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer.
    J Thorac Oncol. 2023 Aug 10:S1556-0864(23)00727.
    >> Share


  158. In the published article titled "New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study", J Thorac Oncol 2019 Jan;15(1):125-129.
    J Thorac Oncol. 2023 Aug 9:S1556-0864(23)00675.
    >> Share

  159. XIE H, Dai C, Gu C, Zhao S, et al
    Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification to Upgrade Extracapsular Extension of Tumor in Nodes From R0 to Incomplete Resection.
    J Thorac Oncol. 2023 Aug 9:S1556-0864(23)00723.
    >> Share

  160. DACIC S, Travis W, Redman M, Saqi A, et al
    International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
    J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
    >> Share

  161. BEARZ A, Martini JF, Jassem J, Kim SW, et al
    Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.
    J Thorac Oncol. 2023 Aug 2:S1556-0864(23)00691.
    >> Share

  162. KUS T, Aktas G
    In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
    J Thorac Oncol. 2023;18:e83-e84.
    >> Share

  163. CONTRUCCI RR, Ter Heine R, Hendriks LEL, de Rouw N, et al
    Folinic Acid to Prevent Pemetrexed-Associated Neutropenia After Intrathecal Administration: A Quick Win.
    J Thorac Oncol. 2023;18:e81-e82.
    >> Share

  164. AKINBOBOLA O, Ray MA, Smeltzer MP, Osarogiagbon RU, et al
    In Response: Taichiro Goto "Kit Use May Not Be Key To Improved Prognosis"; Response to "Akinbobola O, Ray MA, Fehnel C, et al. Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit".
    J Thorac Oncol. 2023;18:e80-e81.
    >> Share

  165. GOTO T
    Kit Use May Not Be Key to Improved Prognosis.
    J Thorac Oncol. 2023;18:e79-e80.
    >> Share

  166. VIDETIC GMM
    Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Become the Standard of Care.
    J Thorac Oncol. 2023;18:986-989.
    >> Share

  167. MACBETH F, Treasure T
    Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Not Become the Standard of Care.
    J Thorac Oncol. 2023;18:981-985.
    >> Share

  168. ISLAM MR, Siddiqua SM, Islam R, Hossain A, et al
    Lung Cancer in Bangladesh.
    J Thorac Oncol. 2023;18:972-980.
    >> Share

  169. TAORMINA JM, Camidge DR
    Editorial Related to Leeuw et al.: The Evolution of Expectations: How Our Views On "Acceptable" Toxicities Are Changing With Prolonged Lung Cancer Treatments.
    J Thorac Oncol. 2023;18:967-969.
    >> Share

  170. BORM FJ, Smit EF
    Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
    J Thorac Oncol. 2023;18:964-966.
    >> Share

  171. NORRIS RP, Dew R, Greystoke A, Todd A, et al
    Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System.
    J Thorac Oncol. 2023;18:990-1002.
    >> Share

  172. PROTO C, Manglaviti S, Lo Russo G, Musca M, et al
    STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
    J Thorac Oncol. 2023;18:1070-1081.
    >> Share

  173. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    J Thorac Oncol. 2023;18:1082-1093.
    >> Share

  174. LIN SH
    Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
    J Thorac Oncol. 2023;18:970-971.
    >> Share

    July 2023
  175. LI A, Wang Y, Yu Z, Tan Z, et al
    STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/IFN-I/CD8(+) T cell Dysfunction in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00688.
    >> Share

  176. RIMNER A, Ruffini E, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
    >> Share

  177. LAM S, Bai C, Baldwin D, Chen Y, et al
    Current and Future Perspectives on CT Screening for Lung Cancer: A Road Map for 2023-2027 from the IASLC.
    J Thorac Oncol. 2023 Jul 22:S1556-0864(23)00687.
    >> Share

  178. AROLT C, Dugan M, Wild R, Richartz V, et al
    KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Jul 18:S1556-0864(23)00684.
    >> Share

  179. LEE JM, McNamee CJ, Toloza E, Negrao MV, et al
    Neoadjuvant Targeted Therapy in Resectable Non-Small Cell Lung Cancer: Current and Future Perspectives.
    J Thorac Oncol. 2023 Jul 12:S1556-0864(23)00671.
    >> Share

  180. SIKOSEK T, Horos R, Trudzinski F, Jehn J, et al
    Early Detection of Lung Cancer using small RNAs.
    J Thorac Oncol. 2023 Jul 10:S1556-0864(23)00670.
    >> Share

  181. RIEDEL R, Fassunke J, Scheel AH, Scheffler M, et al
    Brief Report: MET fusions in Non-small cell lung cancer: Clinicopathologic features and response to MET inhibition.
    J Thorac Oncol. 2023 Jul 8:S1556-0864(23)00666.
    >> Share

  182. EVANS WK, Tammemagi MC, Walker MJ, Cameron E, et al
    Integrating smoking cessation into LDCT lung cancer screening: Results of the Ontario, Canada Pilot.
    J Thorac Oncol. 2023 Jul 6:S1556-0864(23)00669.
    >> Share

  183. WANG CL, Hsu KH, Chang YH, Ho CC, et al
    Low-dose CT screening in relatives with a family history of lung cancer.
    J Thorac Oncol. 2023 Jul 4:S1556-0864(23)00639.
    >> Share

  184. KEOGH RJ, Barr MP, Keogh A, McMahon D, et al
    Lung Cancer in the Republic of Ireland.
    J Thorac Oncol. 2023;18:851-857.
    >> Share

  185. DOWLATI A, Towe CW, Linden PA
    Who Are You "KITTING"? The Use of Kits to Collect Lymph Nodes During Lung Cancer Surgery.
    J Thorac Oncol. 2023;18:838-840.
    >> Share

  186. CHOE JK, Li Y, Adusumilli PS
    Response to Letter to the Editor: "Which Percentage of Micropapillary and Solid Histological Patterns in Lymph Node Metastases Is Significantly Associated With Poor Outcomes?".
    J Thorac Oncol. 2023;18:e76-e77.
    >> Share

  187. NIU Y, He Y, Li Z
    Which Percentage of Micropapillary and Solid Histologic Patterns in Lymph Node Metastases Is Significantly Associated With Poor Outcomes?
    J Thorac Oncol. 2023;18:e75-e76.
    >> Share

  188. ZHAO B, Qi H, Wu J, Ma W, et al
    Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
    J Thorac Oncol. 2023;18:e72-e73.
    >> Share

  189. KUNIMASA K, Wada M, Nishino K
    Severe Psychosis Associated With Lorlatinib.
    J Thorac Oncol. 2023;18:e71-e72.
    >> Share

  190. NADRES B, Momcilovic M, Shackelford DB, Lisberg A, et al
    An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors.
    J Thorac Oncol. 2023;18:847-850.
    >> Share

  191. NORMAN A, Adjei AA
    Expanding the KRASG12C Inhibitor Class: What Do We Need Next?
    J Thorac Oncol. 2023;18:844-846.
    >> Share

  192. COOPER WA, John T
    Rethinking Biomarkers for Combination Chemoimmunotherapy.
    J Thorac Oncol. 2023;18:841-843.
    >> Share

  193. KIM HK
    Selective Mediastinal Lymph Node Dissection: Precision Surgery in the Era of Precision Medicine.
    J Thorac Oncol. 2023;18:834-837.
    >> Share

  194. MINCHOM A, Popat S
    Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?
    J Thorac Oncol. 2023;18:830-833.
    >> Share

  195. LAU BC, Wu YF, No HJ, Ko RB, et al
    Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.
    J Thorac Oncol. 2023;18:922-930.
    >> Share

  196. SUN D, Liu J, Zhou H, Shi M, et al
    Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC.
    J Thorac Oncol. 2023;18:869-881.
    >> Share

    June 2023
  197. GILLESPIE CS, Mustafa MA, Richardson GE, Alam AM, et al
    Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis.
    J Thorac Oncol. 2023 Jun 29:S1556-0864(23)00638.
    >> Share

  198. CHI-LEUNG LAM D, Liam CK, Andarini S, Park S, et al
    Lung Cancer Screening in Asia: An Expert Consensus Report.
    J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00635.
    >> Share

  199. PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
    Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
    J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
    >> Share

  200. HARATANI K, Nakamura A, Mamesaya N, Mitsuoka S, et al
    Tumor microenvironment landscape of non-small cell lung cancer reveals resistance mechanisms for PD-L1 blockade following chemoradiotherapy: a multi-center prospective biomarker study (WJOG11518L/SUBMARINE).
    J Thorac Oncol. 2023 Jun 24:S1556-0864(23)00633.
    >> Share

  201. JUNG HA, Ku BM, Kim YJ, Park S, et al
    Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stage I-IIIA EGFR Mutant-Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Jun 10:S1556-0864(23)00607.
    >> Share

  202. SOO RA, Martini JF, van der Wekken AJ, Teraoka S, et al
    Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive non-small cell lung cancer.
    J Thorac Oncol. 2023 Jun 7:S1556-0864(23)00580.
    >> Share

  203. BERG CD, Schiller JH, Boffetta P, Cai J, et al
    AIR POLLUTION AND LUNG CANCER A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee.
    J Thorac Oncol. 2023 Jun 3:S1556-0864(23)00601.
    >> Share

  204. PICCIRILLO MC, Chu Q, Bradbury P, Seymour L, et al
    Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".
    J Thorac Oncol. 2023;18:e68-e69.
    >> Share

  205. GEMELLI M
    "Brief Report: Canadian Cancer Trials Group IND.227": Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2023;18:e67-e68.
    >> Share

  206. NAKASHIMA K, Tsubata Y, Isobe T
    Successful Pembrolizumab Rechallenge in a Patient With Advanced NSCLC After Pemetrexed-Induced Palm Pustules.
    J Thorac Oncol. 2023;18:e66-e67.
    >> Share

  207. MA Z, Yang X, Hui Z
    Association of Heart Base Dose With Overall Survival in Patients With NSCLC Undergoing Postoperative Radiotherapy.
    J Thorac Oncol. 2023;18:e62-e64.
    >> Share

  208. ZHAO B, Wu J, Ma W
    Clinical and Genomic Factors Predicting the Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
    J Thorac Oncol. 2023;18:e59-e60.
    >> Share

  209. SMELTZER MP, Liao W, Osarogiagbon RU
    In Response: Letter to the Editor: Re "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening".
    J Thorac Oncol. 2023;18:e58-e59.
    >> Share

  210. TRIPHURIDET N, Ou SI
    Reply to "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023;18(2):158-168".
    J Thorac Oncol. 2023;18:e57-e58.
    >> Share

  211. CARBONE M, Yang H, Pass HI, Taioli E, et al
    Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?
    J Thorac Oncol. 2023;18:694-697.
    >> Share

  212. CHIU CH, Yang PC
    Never Say No to Never-Smokers.
    J Thorac Oncol. 2023;18:689-693.
    >> Share

  213. DELASOS L, Madabhushi A, Patil PD
    Can Radiomics Bridge the Gap Between Immunotherapy and Precision Medicine in Lung Cancer?
    J Thorac Oncol. 2023;18:686-688.
    >> Share

  214. LIM JH, Lee S, Ryu JS
    Prediction of Treatment Response to Chemoimmunotherapy: Concerted Effort Needed.
    J Thorac Oncol. 2023;18:682-685.
    >> Share

  215. ACKER F, Althoff FC, Sebastian M
    Systemic Treatment for Brain Metastases in NSCLC: A New Chapter.
    J Thorac Oncol. 2023;18:678-681.
    >> Share

  216. ROLFO C, Russo A
    Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction-Based Testing.
    J Thorac Oncol. 2023;18:674-677.
    >> Share

  217. MAKHARADZE T, Gogishvili M, Melkadze T, Baramidze A, et al
    Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
    J Thorac Oncol. 2023;18:755-768.
    >> Share

  218. PICCIRILLO MC, Chu Q, Bradbury P, Tu W, et al
    Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
    J Thorac Oncol. 2023;18:813-819.
    >> Share

  219. HUANG J, Chan SC, Pang WS, Chow SH, et al
    Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study.
    J Thorac Oncol. 2023;18:792-802.
    >> Share

    May 2023
  220. ALESSI JV, Wang X, Elkrief A, Ricciuti B, et al
    Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer.
    J Thorac Oncol. 2023 May 27:S1556-0864(23)00578.
    >> Share

  221. JOHN T, Grohe C, Goldman JW, Shepherd FA, et al
    Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial.
    J Thorac Oncol. 2023 May 24:S1556-0864(23)00574.
    >> Share

  222. CHOUR A, Denis J, Mascaux C, Zysman M, et al
    Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer.
    J Thorac Oncol. 2023 May 20:S1556-0864(23)00572.
    >> Share

  223. RUDIN CM, Balli D, Lai WV, Richards AL, et al
    Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation.
    J Thorac Oncol. 2023 May 18:S1556-0864(23)00554.
    >> Share

  224. CHENG C, Hong W, Li Y, Xiao X, et al
    Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis.
    J Thorac Oncol. 2023 May 5:S1556-0864(23)00527.
    >> Share

  225. RECK M, Ciuleanu TE, Lee JS, Schenker M, et al
    Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1.
    J Thorac Oncol. 2023 May 3:S1556-0864(23)00525.
    >> Share

  226. GARON EB, Spira AI, Goldberg SB, Chaft JE, et al
    Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial.
    J Thorac Oncol. 2023 May 3:S1556-0864(23)00524.
    >> Share

  227. CHENG C, Nguyen TT, Tang M, Wang X, et al
    Immune infiltration in tumor and adjacent non-neoplastic regions co-determines patient clinical outcomes in early-stage lung cancer.
    J Thorac Oncol. 2023 May 3:S1556-0864(23)00526.
    >> Share

  228. ZHOU F, Zhou C
    Notch Mutations as a Novel Biomarker for Immunotherapy.
    J Thorac Oncol. 2023;18:e54-e56.
    >> Share

  229. KUNIMASA K
    Notch Mutations as a Novel Biomarker for Immunotherapy.
    J Thorac Oncol. 2023;18:e53-e54.
    >> Share

  230. MURCIANO-GOROFF YR, Lin ST, Wilhelm C, Iasonos A, et al
    In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC".
    J Thorac Oncol. 2023;18:e52-e53.
    >> Share

  231. ZHAO B, Xing H, Ma W
    Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion.
    J Thorac Oncol. 2023;18:e51-e52.
    >> Share

  232. YANG CY, Lin YT, Lin LJ, Yang PC, et al
    Response to Letter to the Editor: "Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer".
    J Thorac Oncol. 2023;18:e49-e51.
    >> Share

  233. INAGAKI Y
    Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer.
    J Thorac Oncol. 2023;18:e48-e49.
    >> Share

  234. OKUBO Y, Yatabe Y
    Reply to the Letter to the Editor From He Y et al.
    J Thorac Oncol. 2023;18:e46-e48.
    >> Share

  235. HE Y, Zhang J, Li Z
    The Protective and Risk Factors Affecting the Prognosis of Pathologic Stage IA Adenocarcinoma: How to Balance?
    J Thorac Oncol. 2023;18:e45-e46.
    >> Share

  236. LAU SCM, Ou SI
    Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?
    J Thorac Oncol. 2023;18:561-563.
    >> Share

  237. NAKAJIMA J
    Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis.
    J Thorac Oncol. 2023;18:559-560.
    >> Share

  238. ERASMUS JJ, Vlahos I
    Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
    J Thorac Oncol. 2023;18:556-558.
    >> Share

  239. HORINOUCHI H
    Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2023;18:552-555.
    >> Share

  240. SUN L, Marmarelis M, Aggarwal C
    Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?
    J Thorac Oncol. 2023;18:549-551.
    >> Share

  241. NAIDOO J, Antonia S, Wu YL, Cho BC, et al
    Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    J Thorac Oncol. 2023;18:657-663.
    >> Share

  242. MCWILLIAM A, Abravan A, Banfill K, Faivre-Finn C, et al
    Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival.
    J Thorac Oncol. 2023;18:599-607.
    >> Share

  243. LI Y, Byun AJ, Choe JK, Lu S, et al
    Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients With Stages II to III Lung Adenocarcinoma.
    J Thorac Oncol. 2023;18:608-619.
    >> Share

  244. ZHOU C, Chen G, Huang Y, Zhou J, et al
    Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
    J Thorac Oncol. 2023;18:628-639.
    >> Share

  245. GU Z, Hao X, Liu Y, Xu N, et al
    Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis.
    J Thorac Oncol. 2023;18:640-649.
    >> Share

    April 2023
  246. PARK CK, Oh HJ, Kim YC, Kim YH, et al
    Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR.
    J Thorac Oncol. 2023 Apr 19:S1556-0864(23)00495.
    >> Share

  247. HONG TH, Bang YH, Joe C, Hwang S, et al
    Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2023 Apr 5:S1556-0864(23)00482.
    >> Share

  248. WANG Y, Che G
    Authors' Reply to Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases".
    J Thorac Oncol. 2023;18:e46-e47.
    >> Share

  249. WANG H, Yang R, Li W
    Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases".
    J Thorac Oncol. 2023;18:e44-e45.
    >> Share

  250. HAN DH, Duan F, Patz EF Jr
    Response to Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.
    J Thorac Oncol. 2023;18:e41-e42.
    >> Share

  251. LI Z, He Y, Xiong Z
    Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.
    J Thorac Oncol. 2023;18:e40-e41.
    >> Share

  252. GIRARD N, Garassino MC, Solomon B
    Response to Letter to the Editor From Binghao Zhao et al.
    J Thorac Oncol. 2023;18:e40-e41.
    >> Share

  253. ZHAO B, Li H, Ma W
    Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study.
    J Thorac Oncol. 2023;18:e38-e39.
    >> Share

  254. NG JKM, Chan CF, Li JJX
    Thymic Carcinoma With Malignant Effusion-a Rare Cytologic and Radiologic Mimicker of Metastatic NSCLC.
    J Thorac Oncol. 2023;18:e35-e37.
    >> Share

  255. CHEN CH, Hsu CK, Lee CN
    Tepotinib-Induced Palmoplantar Keratoderma-Like Hand-Foot Skin Reaction.
    J Thorac Oncol. 2023;18:e33-e34.
    >> Share

  256. ZOHRABYAN D, Karapetyan N, Danielyan S, Saghatelyan T, et al
    Lung Cancer in Armenia.
    J Thorac Oncol. 2023;18:402-409.
    >> Share

  257. EBI H
    Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment.
    J Thorac Oncol. 2023;18:399-401.
    >> Share

  258. MOREIRA AL, Sabari JK
    Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures.
    J Thorac Oncol. 2023;18:396-398.
    >> Share

  259. LAU SCM
    The Value of Comprehensive Molecular Profiling in Early Stage Lung Cancer.
    J Thorac Oncol. 2023;18:393-395.
    >> Share

  260. LE X
    Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity.
    J Thorac Oncol. 2023;18:390-392.
    >> Share

  261. VISCA P, Gallo E, Marino M
    New Morphologic Findings Support Invasiveness Criteria in Small-Sized Nonmucinous Lepidic Adenocarcinoma: Commenting a Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2023;18:387-389.
    >> Share

  262. MOGHAL N, Li Q, Stewart EL, Navab R, et al
    Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.
    J Thorac Oncol. 2023;18:499-515.
    >> Share

  263. THUNNISSEN E, Beasley MB, Borczuk A, Dacic S, et al
    Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2023;18:447-462.
    >> Share

  264. CHOUDHURY NJ, Marra A, Sui JSY, Flynn J, et al
    Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
    J Thorac Oncol. 2023;18:463-475.
    >> Share

  265. MUTHUSAMY B, Raskina K, Lofgren KT, Li G, et al
    Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma.
    J Thorac Oncol. 2023;18:476-486.
    >> Share

  266. REMON J, Hendriks LEL, Mountzios G, Garcia-Campelo R, et al
    MET alterations in NSCLC-Current Perspectives and Future Challenges.
    J Thorac Oncol. 2023;18:419-435.
    >> Share

    March 2023
  267. DE LEEUW SP, Pruis MA, Sikkema BJ, Mohseni M, et al
    Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer.
    J Thorac Oncol. 2023 Mar 29:S1556-0864(23)00219.
    >> Share

  268. ZHANG H, Nabel CS, Li D, O'Connor RI, et al
    Histone deacetylase 6 inhibition exploits selective metabolic vulnerabilities in LKB1 mutant, KRAS driven non-small cell lung cancer.
    J Thorac Oncol. 2023 Mar 21:S1556-0864(23)00197.
    >> Share

  269. CORNELISSEN R, Prelaj A, Sun S, Baik C, et al
    Poziotinib in Treatment-Naive Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4).
    J Thorac Oncol. 2023 Mar 21:S1556-0864(23)00199.
    >> Share

  270. LI Z, Song Z, Zhao Y, Wang P, et al
    D-1553 (garsorasib), a Potent and Selective Inhibitor of KRAS(G12C) in Patients with Non-Small Cell Lung Cancer: Phase I Study Results.
    J Thorac Oncol. 2023 Mar 20:S1556-0864(23)00196.
    >> Share

  271. AKINBOBOLA O, Ray MA, Fehnel C, Saulsberry A, et al
    Institution-Level Evolution of Lung Cancer Resection Quality with Implementation of a Lymph Node Specimen Collection Kit.
    J Thorac Oncol. 2023 Mar 15:S1556-0864(23)00191.
    >> Share

  272. ZHAO J, Zhao L, Guo W, Wang S, et al
    Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients with Resectable Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
    J Thorac Oncol. 2023 Mar 2:S1556-0864(23)00161.
    >> Share

  273. OU SI, Kim ES
    Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    J Thorac Oncol. 2023;18:e30-e31.
    >> Share

  274. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
    Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    J Thorac Oncol. 2023;18:e28-e29.
    >> Share

  275. ZHAO B, Wu J, Ma W
    Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib.
    J Thorac Oncol. 2023;18:e26-e27.
    >> Share

  276. ZHANG R, Li Y, Chen F, Christiani DC, et al
    Reply to Scott et al: "Gene-Gene interaction in ever-smokers with lung cancer: Is there confounding by COPD in GWAS?".
    J Thorac Oncol. 2023;18:e24-e26.
    >> Share

  277. YOUNG RP, Scott RJ
    Gene-Gene Interaction in Ever Smokers With Lung Cancer: Is There Confounding by Chronic Obstructive Pulmonary Disease in Genome-Wide Association Studies?
    J Thorac Oncol. 2023;18:e23-e24.
    >> Share

  278. BORILOVA S, Dusek L, Jakubikova L, Turcani P, et al
    Lung Cancer in the Czech Republic.
    J Thorac Oncol. 2023;18:271-277.
    >> Share

  279. GIRARD N
    In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50.
    J Thorac Oncol. 2023;18:268-270.
    >> Share

  280. MARMARELIS ME, Sun L, Aggarwal C
    Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor.
    J Thorac Oncol. 2023;18:265-267.
    >> Share

  281. RAMELLA S, Soda P
    Stage I Stereotactic Body Radiation Therapy Outcome's Prediction Models: Perfection Is the Enemy of Utility.
    J Thorac Oncol. 2023;18:262-264.
    >> Share

  282. YEHIA L, Centomo ML, Pandolfi PP, Eng C, et al
    Two's Company, Three's a Crowd: Rb1/Trp53/Pten Trifecta and Lung Cancer Molecular and Histopathologic Heterogeneity.
    J Thorac Oncol. 2023;18:260-261.
    >> Share

  283. RODEN AC, Molina JR
    Plasma Biomarkers to Monitor Bronchopulmonary Carcinoids-Are We There Yet?
    J Thorac Oncol. 2023;18:257-259.
    >> Share

  284. FRANK MS, Bodtger U
    An Individualized Approach to Comorbidities in Lung Cancer.
    J Thorac Oncol. 2023;18:254-256.
    >> Share

  285. KATZ SI, Straus CM, Roshkovan L, Blyth KG, et al
    Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.
    J Thorac Oncol. 2023;18:278-298.
    >> Share

  286. NISMAN B, Oleinikov K, Nechushtan H, Maimon O, et al
    Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report.
    J Thorac Oncol. 2023;18:369-376.
    >> Share

  287. ZHANG L, Liu C, Zhang B, Zheng J, et al
    PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion.
    J Thorac Oncol. 2023;18:324-338.
    >> Share

  288. FALKSON CB, Vella ET, Ellis PM, Maziak DE, et al
    Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review.
    J Thorac Oncol. 2023;18:299-312.
    >> Share

    February 2023
  289. HE K, Berz D, Gadgeel SM, Iams WT, et al
    MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.
    J Thorac Oncol. 2023 Feb 24:S1556-0864(23)00158.
    >> Share

  290. ZHANG Y, Deng C, Zheng Q, Qian B, et al
    Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A prospective, multicenter, clinical trial.
    J Thorac Oncol. 2023 Feb 23:S1556-0864(23)00138.
    >> Share

  291. ALESSI JV, Elkrief A, Ricciuti B, Wang X, et al
    Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2023 Feb 10:S1556-0864(23)00121.
    >> Share

  292. TRIPHURIDET N, Zhang SS, Nagasaka M, Gao Y, et al
    Low dose computed tomography (LDCT) screening in Asian female never-smokers is as efficacious in detecting lung cancer as in Asian male-ever-smokers: a systematic review and meta-analysis.
    J Thorac Oncol. 2023 Feb 10:S1556-0864(23)00124.
    >> Share

  293. CHEN M, Lu H, Copley SJ, Han Y, et al
    A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity from Programmed Cell Death-1 Pathway Inhibition in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Feb 9:S1556-0864(23)00096.
    >> Share

  294. ASAMURA H, Nishimura KK, Giroux DJ, Chansky K, et al
    IASLC lung cancer staging project: the new database to inform revisions in the ninth edition of the TNM classification of lung cancer.
    J Thorac Oncol. 2023 Feb 9:S1556-0864(23)00097.
    >> Share

  295. IGNATIUS OU SH, Hong JL, Christopoulos P, Lin HM, et al
    Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non-small Cell Lung Cancer.
    J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00095.
    >> Share

  296. HOU X, Zhou C, Wu G, Lin W, et al
    Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Ar
    J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00092.
    >> Share

  297. PROVENZANO L, Damian S, Duca M, Della Valle S, et al
    Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.
    J Thorac Oncol. 2023;18:e9-e10.
    >> Share

  298. HEIDEN BT, Puri V
    Response to "Which Factors Determinate the Lymphadenectomy Definition?".
    J Thorac Oncol. 2023;18:e8-e9.
    >> Share

  299. CHIAPPETTA M, Sassorossi C, Lococo F, Margaritora S, et al
    Which Factors Determinate the Lymphadenectomy Definition? Comment on "Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-Stage Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2023;18:e7-e8.
    >> Share

  300. ZHANG L, Yang X
    Comment on: "Quitting Smoking at or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis".
    J Thorac Oncol. 2023;18:e17-e19.
    >> Share

  301. HIGASHIYAMA RI, Yoshida T, Yagishita S, Hamada A, et al
    In Response: Letter Received From Dr. Charles Ricordel Titled "Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC".
    J Thorac Oncol. 2023;18:e16-e17.
    >> Share

  302. PIERRE C, Goter T, Lena H, Le Guen Y, et al
    Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC.
    J Thorac Oncol. 2023;18:e14-e16.
    >> Share

  303. DE CARLO E, Bertoli E, Chimienti E, Del Conte A, et al
    Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC.
    J Thorac Oncol. 2023;18:e11-e13.
    >> Share

  304. ARTAL-CORTES AF, Verdun-Aguilar J, Marquez-Medina D
    Opening Windows for Thymic Tumors.
    J Thorac Oncol. 2023;18:136-138.
    >> Share

  305. O'LEARY C, Naidoo J
    PACIFIC in the Real World.
    J Thorac Oncol. 2023;18:133-135.
    >> Share

  306. TAN WL, Lim DW
    Is There a Unicorn Among the Uncommon EGFR Mutations?
    J Thorac Oncol. 2023;18:129-132.
    >> Share

  307. NAGASAKA M, Ou SI
    CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib?
    J Thorac Oncol. 2023;18:139-142.
    >> Share

  308. LARSON NB, Oberg AL, Adjei AA, Wang L, et al
    A Clinician's Guide to Bioinformatics for Next-Generation Sequencing.
    J Thorac Oncol. 2023;18:143-157.
    >> Share

  309. MERBOTH F, Nebelung H, Wotschel N, Liebscher H, et al
    Robotic Esophagectomy Compared With Open Esophagectomy Reduces Sarcopenia within the First Postoperative Year: A Propensity Score-Matched Analysis.
    J Thorac Oncol. 2023;18:232-244.
    >> Share

  310. JUNG HA, Kim M, Kim HS, Kim JH, et al
    A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
    J Thorac Oncol. 2023;18:223-231.
    >> Share

  311. BAR J, Peled N, Schokrpur S, Wolner M, et al
    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
    J Thorac Oncol. 2023;18:169-180.
    >> Share

  312. GIRARD N, Bar J, Garrido P, Garassino MC, et al
    Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
    J Thorac Oncol. 2023;18:181-193.
    >> Share

  313. YAN W, Zhong WZ, Liu YH, Chen Q, et al
    Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial.
    J Thorac Oncol. 2023;18:194-203.
    >> Share

    January 2023
  314. KILLINGBERG KT, Gronberg BH, Slaaen M, Kirkevold O, et al
    Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer.
    J Thorac Oncol. 2023 Jan 27:S1556-0864(23)00016.
    >> Share

  315. MURCIANO-GOROFF YR, Falcon CJ, Lin ST, Chacko C, et al
    Original article: Central nervous system disease in patients with RET fusion-positive non-small cell lung cancer treated with selpercatinib.
    J Thorac Oncol. 2023 Jan 16:S1556-0864(23)00008.
    >> Share

  316. ALDEA M, Marinello A, Duruisseaux M, Zrafi W, et al
    RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.
    J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01994.
    >> Share

  317. DERCLE L, Fronheiser M, Rizvi NA, Hellmann MD, et al
    Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer.
    J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01995.
    >> Share

  318. YANKELEVITZ DF, Yip R, Henschke CI
    Impact of Duration of Diagnostic Workup on Prognosis for Early Lung Cancer.
    J Thorac Oncol. 2023 Jan 12:S1556-0864(22)01996.
    >> Share

  319. KIM DW, Kim SW, Camidge DR, Shu CA, et al
    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report.
    J Thorac Oncol. 2023 Jan 11:S1556-0864(22)01997.
    >> Share

  320. KENMOTSU H, Mori K, Nakagawa K, Yamamoto N, et al
    Response to "Letter to the Editor" From David Y. Mak et al.
    J Thorac Oncol. 2023;18:e4-e5.
    >> Share

  321. MAK DY, Tjong MC, Louie AV
    Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations.
    J Thorac Oncol. 2023;18:e3-e4.
    >> Share

  322. ZHAO B, Li H, Wu J, Ma W, et al
    Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial.
    J Thorac Oncol. 2023;18:e1-e2.
    >> Share

  323. AHN JY, Nagasaka M
    Neptune, the Next Pluto?-Durvalumab and Tremelimumab Face Challenges in Entering the NSCLC Space.
    J Thorac Oncol. 2023;18:29-30.
    >> Share

  324. JIA K, Ren S
    Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction?
    J Thorac Oncol. 2023;18:26-28.
    >> Share

  325. OEZKAN F, Seweryn M, Shukuya T, Owen DH, et al
    Improvement in Survival for Patients With Lung Cancer in Taiwan: Implications and Call to Action.
    J Thorac Oncol. 2023;18:21-25.
    >> Share

  326. FERRARA R, Ricciuti B, Ambrogio C, Trapani D, et al
    The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers.
    J Thorac Oncol. 2023;18:17-20.
    >> Share

  327. COLORI A, Hiley C
    The Interaction of Preexisting Cardiac Dysfunction and Heart Dose From Radical Radiotherapy on All-Cause Mortality in Locally Advanced NSCLC.
    J Thorac Oncol. 2023;18:14-16.
    >> Share

  328. BALASUBRAMANIAN A, John T
    Safety of Dueling NSCLC With Dual Agent Immunotherapy.
    J Thorac Oncol. 2023;18:10-13.
    >> Share

  329. DE CASTRO G JR, Rizvi NA, Schmid P, Syrigos K, et al
    NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
    J Thorac Oncol. 2023;18:106-119.
    >> Share

  330. DAGOGO-JACK I, Abbattista A, Murphy JF, Krulewicz S, et al
    Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
    J Thorac Oncol. 2023;18:67-78.
    >> Share

  331. YANG CY, Lin YT, Lin LJ, Chang YH, et al
    Stage Shift Improves Lung Cancer Survival: Real-World Evidence.
    J Thorac Oncol. 2023;18:47-56.
    >> Share

    December 2022
  332. OSAROGIAGBON RU, Van Schil P, Giroux DJ, Lim E, et al
    The IASLC Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer.
    J Thorac Oncol. 2022 Dec 23:S1556-0864(22)01985.
    >> Share

  333. ERNST SM, Mankor J, van Riet J, von der Thusen JH, et al
    Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.
    J Thorac Oncol. 2022 Dec 14:S1556-0864(22)01961.
    >> Share

  334. DEB D, Moore AC, Basu Roy U
    In Response: Letter Received From Dr. Tadashi Nishimura Titled "What About Palliative and Supportive Care Landscapes?".
    J Thorac Oncol. 2022;17:e95-e96.
    >> Share

  335. NISHIMURA T
    What About Palliative and Supportive Care Landscapes?
    J Thorac Oncol. 2022;17:e95.
    >> Share

  336. GROSSO F, Cerbone L, Pasello G
    Pericardial Mesothelioma, a Disease for Brave Hearts.
    J Thorac Oncol. 2022;17:1333-1334.
    >> Share

  337. BOGART JA
    Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?
    J Thorac Oncol. 2022;17:1330-1332.
    >> Share

  338. OFFIN M, De Silva DL, Sauter JL, Egger JV, et al
    Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
    J Thorac Oncol. 2022;17:1428-1432.
    >> Share

  339. LIN EP, Hsu CY, Chiou JF, Berry L, et al
    Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit.
    J Thorac Oncol. 2022;17:1365-1374.
    >> Share

  340. GARASSINO MC, Mazieres J, Reck M, Chouaid C, et al
    Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
    J Thorac Oncol. 2022;17:1415-1427.
    >> Share

    November 2022
  341. FOUSEK K, Horn LA, Qin H, Dahut M, et al
    An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC).
    J Thorac Oncol. 2022 Nov 18:S1556-0864(22)01910.
    >> Share

  342. GARCIA-PARDO M, Chang A, Schmid S, Dong M, et al
    Respiratory and cardiometabolic comorbidities and Stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO).
    J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01903.
    >> Share

  343. GAO S, Jin L, Meadows HW, Shafman T, et al
    Prediction of distant metastases after stereotactic body radiation therapy for early stage non-small cell lung cancer: development and external validation of a multi-institutional model.
    J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01909.
    >> Share

  344. MITSUDOMI T, Tan D, Yang JC, Ahn MJ, et al
    Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.
    J Thorac Oncol. 2022 Nov 12. pii: S1556-0864(22)01905.
    >> Share

    October 2022
  345. WANG Q, Gumus ZH, Colarossi C, Memeo L, et al
    Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection.
    J Thorac Oncol. 2022 Oct 12. pii: S1556-0864(22)01851.
    >> Share

  346. PAIK PK, Fan PD, Qeriqi B, Namakydoust A, et al
    Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.
    J Thorac Oncol. 2022 Oct 11. pii: S1556-0864(22)01825.
    >> Share

  347. HOPKINS AM, Sorich MJ
    Response to Mazzaschi and Buti.
    J Thorac Oncol. 2022;17:e90.
    >> Share

  348. MAZZASCHI G, Buti S
    What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?
    J Thorac Oncol. 2022;17:e89-e90.
    >> Share

  349. SUMI T, Michimata H, Nagayama D, Koshino Y, et al
    Tumor-Associated Raynaud's Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:1233-1234.
    >> Share

  350. FENG J, Leighl NB
    There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor.
    J Thorac Oncol. 2022;17:1175-1177.
    >> Share

  351. DAGOGO-JACK I, Piotrowska Z
    There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC.
    J Thorac Oncol. 2022;17:1171-1174.
    >> Share

  352. CANGIR AK, Yumuk PF, Sak SD, Akyurek S, et al
    Lung Cancer in Turkey.
    J Thorac Oncol. 2022;17:1158-1170.
    >> Share

  353. MOUNTZIOS G, Aggarwal C
    Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?
    J Thorac Oncol. 2022;17:1155-1157.
    >> Share

  354. LAU SCM, Ou SI
    And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
    J Thorac Oncol. 2022;17:1144-1154.
    >> Share

    September 2022
  355. SMELTZER MP, Liao W, Faris NR, Fehnel C, et al
    Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    J Thorac Oncol. 2022 Sep 30. pii: S1556-0864(22)01820.
    >> Share

  356. ZHOU C, Huang D, Fan Y, Yu X, et al
    Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.
    J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01803.
    >> Share

  357. MINO-KENUDSON M, Schalper K, Cooper W, Dacic S, et al
    Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.
    J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01695.
    >> Share

  358. CRADDOCK M, Nestle U, Koenig J, Schimek-Jasch T, et al
    Cardiac function modifies the impact of heart base dose on survival: A voxel-wise analysis of lung cancer patients from the PET-Plan trial.
    J Thorac Oncol. 2022 Sep 18. pii: S1556-0864(22)01590.
    >> Share

  359. IGNATIUS OU SH, Nishio M, Ahn MJ, Mok T, et al
    Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.
    J Thorac Oncol. 2022 Sep 9. pii: S1556-0864(22)01584.
    >> Share

  360. IGNATIUS OU SH
    In Response to Continuation of Lorlatinib Beyond Progressive Disease.
    J Thorac Oncol. 2022;17:e86-e88.
    >> Share

  361. ZHAO B, Ma W
    Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
    J Thorac Oncol. 2022;17:e85-e86.
    >> Share

  362. BOZINOVSKI S
    Response to "Non-Tumor Cells in Tumor Specimens Impair the Accuracy of qPCR in the Detection of PD-L1 CNV and mRNA Expression".
    J Thorac Oncol. 2022;17:e84-e85.
    >> Share

  363. ZHANG H, Chen Z, Li M, Sui Q, et al
    Nontumor cells in Tumor Specimens Impair the Accuracy of Quantitative Polymerase Chain Reaction in the Detection of Programmed Death-Ligand 1 Copy Number Variant and mRNA Expression.
    J Thorac Oncol. 2022;17:e83-e84.
    >> Share

  364. NICHOLSON AG, Scagliotti G, Tsao MS, Yatabe Y, et al
    2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification.
    J Thorac Oncol. 2022;17:e80-e83.
    >> Share

  365. JAVEY M, Yaung SJ
    Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer.
    J Thorac Oncol. 2022;17:e79-e80.
    >> Share

  366. ZHAO B, Xing H, Ma W
    Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.
    J Thorac Oncol. 2022;17:e76-e77.
    >> Share

  367. LEE J, Hong YS, Cho J, Lee J, et al
    Comment on "Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?"
    J Thorac Oncol. 2022;17:e74-e75.
    >> Share

  368. CHIAPPETTA M, Sassorossi C, Tabacco D, Lococo F, et al
    Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?
    J Thorac Oncol. 2022;17:e73-e74.
    >> Share

  369. LEE J, Ahn MJ
    A Response to the Letter to the Editor: "Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2022;17:e72-e73.
    >> Share

  370. ZHAO B, Li H, Ma W
    Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC.
    J Thorac Oncol. 2022;17:e71-e72.
    >> Share

  371. NIYIBIZI BA, Muhizi E, Ndoli DA, Rukundo I, et al
    Lung Cancer in Rwanda.
    J Thorac Oncol. 2022;17:1074-1077.
    >> Share

  372. MATSUOKA R, Kawai H, Ito T, Matsubara D, et al
    Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors.
    J Thorac Oncol. 2022;17:1070-1073.
    >> Share

  373. GIRARD N
    EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents.
    J Thorac Oncol. 2022;17:1067-1069.
    >> Share

  374. WU TC, Lin CC
    Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2022;17:1063-1066.
    >> Share

  375. KALCHIEM-DEKEL O, Falcon CJ, Bestvina CM, Liu D, et al
    Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2022;17:1130-1136.
    >> Share

  376. BAINE MK, Febres-Aldana CA, Chang JC, Jungbluth AA, et al
    POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
    J Thorac Oncol. 2022;17:1109-1121.
    >> Share

    August 2022
  377. PAZ-ARES LG, Ciuleanu T, Pluzanski A, Lee JS, et al
    Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01556.
    >> Share

  378. HEIDEN BT, Eaton DB Jr, Chang SH, Yan Y, et al
    Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-stage Non-small Cell Lung Cancer.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01551.
    >> Share

  379. VACHANI A, Carroll NM, Simoff MJ, Neslund-Dudas C, et al
    Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose CT Screening.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01553.
    >> Share

  380. REDIN E, Garrido-Martin EM, Valencia K, Redrado M, et al
    YES1 is a druggable oncogenic target in Small Cell Lung Cancer.
    J Thorac Oncol. 2022 Aug 18. pii: S1556-0864(22)01530.
    >> Share

  381. SHI Y, Chen G, Wang X, Liu Y, et al
    Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
    J Thorac Oncol. 2022 Aug 3. pii: S1556-0864(22)01496.
    >> Share

  382. SMELTZER MP, Ray MA, Faris NR, Osarogiagbon RU, et al
    Genie Out of the Bottle: Is There a Role for Gene-Gene Interactions in Early Detection of Lung Cancer?
    J Thorac Oncol. 2022;17:946-948.
    >> Share

  383. ROE OD, Creaney J
    Response to "Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma".
    J Thorac Oncol. 2022;17:e69-e70.
    >> Share

  384. YANG H, Yao F, Peng RW
    Revisiting "BAP1ness" in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2022;17:e67-e69.
    >> Share

  385. YANG H, Gaudino G, Bardelli F, Carbone M, et al
    Does the Amount of Asbestos Exposure Influence Prognosis?
    J Thorac Oncol. 2022;17:949-952.
    >> Share

  386. SAVARI O, Chang JC, Bishop JA, Sakthivel MK, et al
    First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
    J Thorac Oncol. 2022;17:1050-1053.
    >> Share

  387. BARBIERI PG, Consonni D, Somigliana A
    Asbestos Lung Burden Does Not Predict Survival in Malignant Pleural Mesothelioma: A Necropsy-Based Study of 185 Cases.
    J Thorac Oncol. 2022;17:1042-1049.
    >> Share

  388. BUCKNELL NW, Belderbos J, Palma DA, Iyengar P, et al
    Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective.
    J Thorac Oncol. 2022;17:961-973.
    >> Share

  389. LAAKSONEN S, Kettunen E, Sutinen E, Ilonen I, et al
    Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2022;17:1032-1041.
    >> Share

    July 2022
  390. PASTORINO U, Ladisa V, Trussardo S, Sabia F, et al
    Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial.
    J Thorac Oncol. 2022 Jul 21. pii: S1556-0864(22)00346.
    >> Share

  391. XIONG A, Ren S, Liu H, Miao L, et al
    Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00327.
    >> Share

  392. VOTH PARK J, Chandra R, Cai L, Ganguly D, et al
    Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00315.
    >> Share

  393. CAVIC M, Kovacevic T, Zaric B, Stojiljkovic D, et al
    Lung Cancer in Serbia.
    J Thorac Oncol. 2022;17:867-872.
    >> Share

  394. NIHO S
    Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy.
    J Thorac Oncol. 2022;17:865-866.
    >> Share

  395. GHAFOOR A, Hassan R
    Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy.
    J Thorac Oncol. 2022;17:862-864.
    >> Share

  396. LOUW A, Panou V, Szejniuk WM, Meristoudis C, et al
    BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
    J Thorac Oncol. 2022;17:921-930.
    >> Share

  397. CARBONE M, Pass HI, Ak G, Alexander HR Jr, et al
    Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
    J Thorac Oncol. 2022;17:873-889.
    >> Share

  398. HIGASHIYAMA RI, Yoshida T, Yagishita S, Ohuchi M, et al
    Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer.
    J Thorac Oncol. 2022 Jul 1. pii: S1556-0864(22)00314.
    >> Share

    June 2022
  399. FERNANDEZ AI, Gavrielatou N, McCann L, Shafi S, et al
    PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer.
    J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00311.
    >> Share

  400. RECK M, Mok TSK, Mansfield A, De Boer R, et al
    Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.
    J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00300.
    >> Share

  401. HIBINO M, Uryu K, Takeda T, Kunimatsu Y, et al
    Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    J Thorac Oncol. 2022 Jun 22. pii: S1556-0864(22)00295.
    >> Share

  402. LU S, Zhang Y, Zhang G, Zhou J, et al
    Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.
    J Thorac Oncol. 2022 Jun 17. pii: S1556-0864(22)00297.
    >> Share

  403. CARDONA AF, Mejia SA, Viola L, Chamorro DF, et al
    Lung Cancer in Colombia.
    J Thorac Oncol. 2022 Jun 15. pii: S1556-0864(22)00217.
    >> Share

  404. NGUYEN EM, Taniguchi H, Chan JM, Zhan YA, et al
    Targeting LSD1 rescues MHC class I antigen presentation and overcomes PD-L1 blockade resistance in small cell lung cancer.
    J Thorac Oncol. 2022 Jun 9. pii: S1556-0864(22)00273.
    >> Share

  405. RICCIUTI B, Awad MM
    Reply to Kus and Aktas.
    J Thorac Oncol. 2022;17:e64-e65.
    >> Share

  406. KUS T, Aktas G
    Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    J Thorac Oncol. 2022;17:e63-e64.
    >> Share

  407. MOK T
    In Response to Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
    J Thorac Oncol. 2022;17:e62-e63.
    >> Share

  408. LI M
    Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
    J Thorac Oncol. 2022;17:e61-e62.
    >> Share

  409. CANDAL-PEDREIRA C, Ruano-Ravina A, Provencio M, Fernandez-Villar A, et al
    Does the Age of Inclusion in Lung Cancer Screening Studies Overestimate the Benefits?
    J Thorac Oncol. 2022;17:e59-e61.
    >> Share

  410. SALEH MM, Scheffler M, Merkelbach-Bruse S, Wolf J, et al
    Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously".
    J Thorac Oncol. 2022;17:e57-e59.
    >> Share

  411. BRADA M, Forbes H, Ashley S, Fenwick J, et al
    Robust Comprehensive Dataset Provides Pause for Thought.
    J Thorac Oncol. 2022;17:e56-e57.
    >> Share

  412. SALEM A, Franks K, Greystoke A, Hanna GG, et al
    Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC.
    J Thorac Oncol. 2022;17:e55-e56.
    >> Share

  413. WRIGHT GM, Goodwin D
    Response to Letter: Beyond "Personalized" to "Tumoralized" Therapy.
    J Thorac Oncol. 2022;17:e54.
    >> Share

  414. GOTO T
    Beyond Personalized to "Tumoralized" Therapy.
    J Thorac Oncol. 2022;17:e53-e54.
    >> Share

  415. FROST N, Griesinger F, Hoffmann H, Langer F, et al
    Lung Cancer in Germany.
    J Thorac Oncol. 2022;17:742-750.
    >> Share

  416. CORTELLINI A, Facchinetti F, Derosa L, Pinato DJ, et al
    Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters.
    J Thorac Oncol. 2022;17:739-741.
    >> Share

  417. ATAY SM, Kim AW
    Possibly Two Birds or One Squirrel.
    J Thorac Oncol. 2022;17:737-738.
    >> Share

  418. RITTBERG R, Abraham N, Laskin J, Ho C, et al
    Hyper-Sensitive? Targeted Therapy With a Primed Immune System.
    J Thorac Oncol. 2022;17:734-736.
    >> Share

  419. VOKES NI, Chambers E, Nguyen T, Coolidge A, et al
    Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2022;17:779-792.
    >> Share

  420. RUFFINI E, Rami-Porta R, Huang J, Ahmad U, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2022;17:838-851.
    >> Share

  421. SHIN DW, Cho JH, Ha J, Jung KW, et al
    Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017.
    J Thorac Oncol. 2022;17:827-837.
    >> Share

  422. SHI Y, Li B, Wu L, Pan Y, et al
    Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer: a multicenter, single-arm, phase 2b study.
    J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00267.
    >> Share

  423. PICCIRILLO MC, Bonanno L, Garassino MC, Esposito G, et al
    Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.
    J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00268.
    >> Share

    May 2022
  424. KENMOTSU H, Wakuda K, Mori K, Kato T, et al
    Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.
    J Thorac Oncol. 2022 May 27. pii: S1556-0864(22)00265.
    >> Share

  425. ZHANG F, Guo W, Zhou B, Wang S, et al
    Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2022 May 9. pii: S1556-0864(22)00216.
    >> Share

  426. SHEIKH HS, Munawar K, Sheikh F, Qamar MFU, et al
    Lung Cancer in Pakistan.
    J Thorac Oncol. 2022;17:602-607.
    >> Share

  427. POLERI C
    Sex-Based Differences in Lung Cancer: Does It Matter?
    J Thorac Oncol. 2022;17:599-601.
    >> Share

  428. EVANS WK, Warren GW, Dresler C
    Ignoring the Obvious: Smoking Cessation Improves Survival.
    J Thorac Oncol. 2022;17:596-598.
    >> Share

  429. WOODARD GA, Cho C, Chen L
    Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
    J Thorac Oncol. 2022;17:592-595.
    >> Share

  430. ZHANG C, Wu YL, Zhong WZ
    New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019.
    J Thorac Oncol. 2022;17:588-591.
    >> Share

  431. FUJIKAWA R, Muraoka Y, Kashima J, Yoshida Y, et al
    Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the International Association for the Study of Lung Cancer Grading System.
    J Thorac Oncol. 2022;17:700-707.
    >> Share

  432. RODEN AC, Ahmad U, Cardillo G, Girard N, et al
    Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.
    J Thorac Oncol. 2022;17:637-650.
    >> Share

  433. AUJLA S, Aloe C, Vannitamby A, Hendry S, et al
    Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.
    J Thorac Oncol. 2022;17:675-687.
    >> Share

  434. SAUTER JL, Dacic S, Galateau-Salle F, Attanoos RL, et al
    The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
    J Thorac Oncol. 2022;17:608-622.
    >> Share

    April 2022
  435. ZHANG R, Shen S, Wei Y, Zhu Y, et al
    A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians.
    J Thorac Oncol. 2022 Apr 29. pii: S1556-0864(22)00215.
    >> Share

  436. MOUTAFI M, Martinez-Morilla S, Divakar P, Vathiotis I, et al
    Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling.
    J Thorac Oncol. 2022 Apr 28. pii: S1556-0864(22)00212.
    >> Share

  437. DEB D, Moore AC, Roy UB
    2021 global lung cancer therapy landscape.
    J Thorac Oncol. 2022 Apr 27. pii: S1556-0864(22)00211.
    >> Share

  438. LEE J, Hong YS, Cho J, Lee J, et al
    Reclassifying the IASLC R Classification According to the Extent of Nodal Dissection for Non-Small Cell Lung Cancer: One Size Does Not Fit All.
    J Thorac Oncol. 2022 Apr 21. pii: S1556-0864(22)00195.
    >> Share

  439. LEE J, Koh J, Kim HK, Hong S, et al
    Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.
    J Thorac Oncol. 2022 Apr 12. pii: S1556-0864(22)00193.
    >> Share

  440. ELHASSAN MMA, Mohamedani AA, Mohamed SAH, Hamdoun AOA, et al
    Lung Cancer in Sudan.
    J Thorac Oncol. 2022;17:489-498.
    >> Share

  441. REGUART N, Reyes R
    Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:477-480.
    >> Share

  442. YANG SR, Rekhtman N
    Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management.
    J Thorac Oncol. 2022;17:e50-e51.
    >> Share

  443. GOTO T
    Genomically Metastatic, but Surgically Curable?
    J Thorac Oncol. 2022;17:e49-e50.
    >> Share

  444. LIN Y, Fu M, Inoue K, Jeon CY, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e47-e48.
    >> Share

  445. TANG W, Lu L, Gu JW, Chen HL, et al
    Some Thoughts Concerning the Patient Adherence to Lung Computed Tomography Screening Reporting and Data System-Recommended Screening Intervals.
    J Thorac Oncol. 2022;17:e45-e46.
    >> Share

  446. ROSNER S, Forde PM
    Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
    J Thorac Oncol. 2022;17:503-509.
    >> Share

  447. HENDRIKS LEL, Remon J, Reck M
    Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
    J Thorac Oncol. 2022;17:499-502.
    >> Share

  448. PUTORA PM, De Ruysscher DK
    Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?
    J Thorac Oncol. 2022;17:487-488.
    >> Share

  449. WANG F, Zhou Q
    The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
    J Thorac Oncol. 2022;17:481-486.
    >> Share

  450. OU SI, Solomon BJ, Shaw AT, Gadgeel SM, et al
    Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
    J Thorac Oncol. 2022;17:568-577.
    >> Share

  451. FOLCH EE, Bowling MR, Pritchett MA, Murgu SD, et al
    NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States.
    J Thorac Oncol. 2022;17:519-531.
    >> Share

  452. MALESZEWSKI JJ, Basso C, Bois MC, Glass C, et al
    The 2021 WHO Classification of Tumors of the Heart.
    J Thorac Oncol. 2022;17:510-518.
    >> Share

    March 2022
  453. SCALERA S, Mazzotta M, Cortile C, Krasniqi E, et al
    Concise Review: Gene of The Month KEAP1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub.
    J Thorac Oncol. 2022 Mar 26. pii: S1556-0864(22)00166.
    >> Share

  454. JAIN D, Nambirajan A, Chen G, Geisinger K, et al
    Non-small cell lung carcinoma subtyping in conventional cytology: Results of the IASLC Cytology Working Group survey to determine specific cytomorphological criteria for adenocarcinoma and squamous cell carcinoma.
    J Thorac Oncol. 2022 Mar 21. pii: S1556-0864(22)00145.
    >> Share

  455. LU S, Zhou Q, Liu X, Du Y, et al
    Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.
    J Thorac Oncol. 2022 Mar 17. pii: S1556-0864(22)00147.
    >> Share

  456. DETTERBECK FC, Nishimura KK, Cilento VJ, Giuliani M, et al
    The IASLC Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the 9(th) Edition TNM Classification.
    J Thorac Oncol. 2022 Mar 9. pii: S1556-0864(22)00107.
    >> Share

  457. SCALERA S, Mazzotta M, Cappuzzo F, Ciliberto G, et al
    KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".
    J Thorac Oncol. 2022;17:e40-e41.
    >> Share

  458. HORINOUCHI H, Kusumoto M, Yatabe Y, Aokage K, et al
    Lung Cancer in Japan.
    J Thorac Oncol. 2022;17:353-361.
    >> Share

  459. TEN HAAF K
    Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer.
    J Thorac Oncol. 2022;17:345-347.
    >> Share

  460. PELOSI G
    Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull's-Eye, Not Shoot in the Dark.
    J Thorac Oncol. 2022;17:e41-e44.
    >> Share

  461. LE X, Heymach J
    In Response.
    J Thorac Oncol. 2022;17:e39.
    >> Share

  462. FERRARA R, Milani M, Garassino MC, Colombo MP, et al
    Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
    J Thorac Oncol. 2022;17:e35-e38.
    >> Share

  463. FAN C, Zhao Q, Teng C, Jiang Z, et al
    Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?"
    J Thorac Oncol. 2022;17:e33-e34.
    >> Share

  464. PAN Z
    Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases From NSCLC.
    J Thorac Oncol. 2022;17:e31-e32.
    >> Share

  465. ZHANG Y, Deng C, Zheng Q, Li Y, et al
    The Grading System of Lung Adenocarcinoma: Ever-Evolving Concepts.
    J Thorac Oncol. 2022;17:e30.
    >> Share

  466. LI S, Deng J, She Y, Hou L, et al
    Clinical Thoughts on the Predictive Value of the Newly Proposed Grading System of Invasive Pulmonary Adenocarcinoma.
    J Thorac Oncol. 2022;17:e28-e29.
    >> Share

  467. LIN Y, Fu M, Inoue K, Jeon CY, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e27-e28.
    >> Share

  468. RAJAGOPAL MS, Senthilnathan R, Km G, Ram M R, et al
    Conceptual and Statistical Interpretation of a Systematic Review and Meta-Analysis on Patient Adherence to Lung-RADS-Recommended Screening Intervals in the United States.
    J Thorac Oncol. 2022;17:e25-e27.
    >> Share

  469. DZIADZIUSZKO R
    STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
    J Thorac Oncol. 2022;17:351-352.
    >> Share

  470. CAMIDGE DR
    The Magic of ADAURA?
    J Thorac Oncol. 2022;17:348-350.
    >> Share

  471. LU S, Li Z
    Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.
    J Thorac Oncol. 2022;17:341-344.
    >> Share

  472. TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
    Reprint of "Introduction to 2021 WHO Classification of Thoracic Tumors".
    J Thorac Oncol. 2022;17:337-340.
    >> Share

  473. NICHOLSON AG, Tsao MS, Beasley MB, Borczuk AC, et al
    The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.
    J Thorac Oncol. 2022;17:362-387.
    >> Share

  474. LU S, Wang Q, Zhang G, Dong X, et al
    Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
    J Thorac Oncol. 2022;17:411-422.
    >> Share

  475. KOSARI F, Disselhorst M, Yin J, Peikert T, et al
    Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:446-454.
    >> Share

  476. RICCIUTI B, Arbour KC, Lin JJ, Vajdi A, et al
    Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    J Thorac Oncol. 2022;17:399-410.
    >> Share

  477. WU YL, John T, Grohe C, Majem M, et al
    Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
    J Thorac Oncol. 2022;17:423-433.
    >> Share

  478. OFFIN M, Yang SR, Egger J, Jayakumaran G, et al
    Molecular Characterization of Peritoneal Mesotheliomas.
    J Thorac Oncol. 2022;17:455-460.
    >> Share

  479. HU ZI, Miettinen M, Quezado M, Lebensohn AP, et al
    Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
    J Thorac Oncol. 2022;17:461-466.
    >> Share

    February 2022
  480. MCCOACH CE, Rolfo C, Drilon A, Lacouture M, et al
    Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001.
    J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00094.
    >> Share

  481. HOPKINS AM, Badaoui S, Kichenadasse G, Karapetis CS, et al
    Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunothera
    J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00093.
    >> Share

  482. SMELTZER MP, Scagliotti GV, Wakelee HA, Mitsudomi T, et al
    International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00086.
    >> Share

  483. AHN MJ, Cho BC, Ou X, Walding A, et al
    Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00081.
    >> Share

  484. SHI Y, Zhao Y, Yang S, Zhou J, et al
    Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00084.
    >> Share

  485. YU XQ, Yap ML, Cheng ES, Ngo PJ, et al
    Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort.
    J Thorac Oncol. 2022 Feb 3. pii: S1556-0864(22)00085.
    >> Share

  486. KERPEL-FRONIUS A, Tammemagi MC, Cavic M, Huber RM, et al
    Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e20-e21.
    >> Share

  487. FU F, Zhang Y, He N, Chen H, et al
    Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed.
    J Thorac Oncol. 2022;17:e18-e20.
    >> Share

  488. NAVANI N, Baldwin DR, Edwards JG, Evison M, et al
    Lung Cancer in the United Kingdom.
    J Thorac Oncol. 2022;17:186-193.
    >> Share

  489. DERKS JL, Dingemans AC, Speel EM
    Molecular Knowledge and Clinical Relevance - Stepping Stones in Improving Classification of Lung Neuroendocrine Neoplasms.
    J Thorac Oncol. 2022;17:e8-e10.
    >> Share

  490. PELOSI G
    The Natural History in Lung Neuroendocrine Neoplasms: The Stone Guest Who Matters.
    J Thorac Oncol. 2022;17:e5-e8.
    >> Share

  491. MOONEN L, Derks JL, Dingemans AC, Speel EJM, et al
    Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull's Eye.
    J Thorac Oncol. 2022;17:e21-e23.
    >> Share

  492. LIN A, Luo P, Zhang J
    Survival Analysis of TP53 Comutations Should Be Interpreted More Cautiously.
    J Thorac Oncol. 2022;17:e14-e18.
    >> Share

  493. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
    J Thorac Oncol. 2022;17:e12-e14.
    >> Share

  494. NARDONE V, Correale P, Mutti L, Desideri I, et al
    Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
    J Thorac Oncol. 2022;17:e10-e12.
    >> Share

  495. FAIVRE-FINN C, Edwards JG, Hatton M
    Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC.
    J Thorac Oncol. 2022;17:197-199.
    >> Share

  496. LIU J, Ladbury C, Kim J, Raz D, et al
    Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
    J Thorac Oncol. 2022;17:194-196.
    >> Share

  497. NAGASAKA M, Ou SI
    Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.
    J Thorac Oncol. 2022;17:182-185.
    >> Share

  498. MUTHUSAMY B, Pennell N
    Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer.
    J Thorac Oncol. 2022;17:179-181.
    >> Share

  499. LIN YT, Shih JY
    Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One.
    J Thorac Oncol. 2022;17:176-178.
    >> Share

  500. LASVERGNAS J, Playe M, Saint-Val L, Brillet PY, et al
    Pitfalls in Cancer Evaluation in Case of Chronic Superior Vena Cava Obstruction: Vertebral Enhancement and Hot Quadrate Sign in the Liver.
    J Thorac Oncol. 2022;17:324-326.
    >> Share

  501. MARX A, Chan JKC, Chalabreysse L, Dacic S, et al
    The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
    J Thorac Oncol. 2022;17:200-213.
    >> Share

  502. NOGAMI N, Barlesi F, Socinski MA, Reck M, et al
    IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
    J Thorac Oncol. 2022;17:309-323.
    >> Share

    January 2022
  503. BRADA M, Forbes H, Ashley S, Fenwick J, et al
    Improving outcomes in non-small cell lung cancer; optimum dose fractionation in radical radiotherapy matters.
    J Thorac Oncol. 2022 Jan 26. pii: S1556-0864(22)00051.
    >> Share

  504. WHISENANT JG, Baena J, Cortellini A, Huang LC, et al
    A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
    J Thorac Oncol. 2022 Jan 24. pii: S1556-0864(22)00033.
    >> Share

  505. SHILPAKAR R, Paudel BD, Sharma R, Silwal SR, et al
    Lung Cancer in Nepal.
    J Thorac Oncol. 2022;17:22-29.
    >> Share

  506. MASAGO K, Fujita S
    Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.
    J Thorac Oncol. 2022;17:16-18.
    >> Share

  507. SALLOUM RG, Braithwaite D
    Expansion of Guideline-Recommended Lung Cancer Screening Eligibility: Implications for Health Equity of Joint Screening and Cessation Interventions.
    J Thorac Oncol. 2022;17:13-15.
    >> Share

  508. TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
    Introduction to 2021 WHO Classification of Thoracic Tumors.
    J Thorac Oncol. 2022;17:e1-e4.
    >> Share

  509. FENNELL DA, Dulloo S
    Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    J Thorac Oncol. 2022;17:34-37.
    >> Share

  510. BAAS P
    Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    J Thorac Oncol. 2022;17:30-33.
    >> Share

  511. JOUBERT P, Travis WD
    Prognostic Impact of Ground-Glass Opacity/Lepidic Component in Pulmonary Adenocarcinoma: A Hazy Staging Dilemma.
    J Thorac Oncol. 2022;17:19-21.
    >> Share

  512. YAMAMOTO H, Togashi Y
    Programmed Death-Ligand 1-Rich Premetastatic Niche in Adjuvant Chemotherapy.
    J Thorac Oncol. 2022;17:10-12.
    >> Share

  513. GROSS DJ, Chintala NK, Vaghjiani RG, Grosser R, et al
    Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.
    J Thorac Oncol. 2022;17:89-102.
    >> Share

  514. OKUBO Y, Kashima J, Teishikata T, Muraoka Y, et al
    Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma.
    J Thorac Oncol. 2022;17:67-75.
    >> Share

  515. LIN Y, Fu M, Ding R, Inoue K, et al
    Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2022;17:38-55.
    >> Share

    December 2021
  516. CHO BC, Han JY, Kim SW, Lee KH, et al
    A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021 Dec 24. pii: S1556-0864(21)03403.
    >> Share

  517. CAINI S, Del Riccio M, Vettori V, Scotti V, et al
    Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis.
    J Thorac Oncol. 2021 Dec 17. pii: S1556-0864(21)03404.
    >> Share

  518. REN S, Chen J, Xu X, Jiang T, et al
    Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.
    J Thorac Oncol. 2021 Dec 16. pii: S1556-0864(21)03392.
    >> Share

  519. EBERL M, Tanaka LF, Kraywinkel K, Klug SJ, et al
    Incidence of smoking-related second primary cancers after lung cancer in Germany: an analysis of nationwide cancer registry data.
    J Thorac Oncol. 2021 Dec 10. pii: S1556-0864(21)03390.
    >> Share

  520. HUBER RM, Cavic M, Kerpel-Fronius A, Viola L, et al
    Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Dec 2. pii: S1556-0864(21)03326.
    >> Share

  521. PARK S, Choi CM, Hwang SS, Choi YL, et al
    Lung Cancer in Korea.
    J Thorac Oncol. 2021;16:1988-1993.
    >> Share

  522. BIAN Y, Liang J, Shan G, Zhan C, et al
    Combining Clinical and Molecular Characteristics to Precisely Predict the Prognosis of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:e99-e100.
    >> Share

  523. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Encouraging Guideline-Concordant Treatment for T3 NSCLC.
    J Thorac Oncol. 2021;16:e98-e99.
    >> Share

  524. LI M, Liang J, Bi G, Zhan C, et al
    Could T3Satell Tumors Be Considered Reclassified as T2b?
    J Thorac Oncol. 2021;16:e97-e98.
    >> Share

  525. MORGENSZTERN D, Govindan R
    Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
    J Thorac Oncol. 2021;16:1999-2001.
    >> Share

  526. AREDO JV, Hellyer JA, Neal JW, Wakelee HA, et al
    Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1994-1998.
    >> Share

  527. BELDA-SANCHIS J, Trujillo-Reyes JC, Martinez-Tellez E, Cladellas-Gutierrez E, et al
    Brain Metastasis From Thymic Epithelial Tumors: Strengthening the Evidence, a Call for Action.
    J Thorac Oncol. 2021;16:1984-1987.
    >> Share

  528. PELOSI G
    KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
    J Thorac Oncol. 2021;16:1979-1983.
    >> Share

  529. BUGLIONI S, Marino M
    Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community.
    J Thorac Oncol. 2021;16:1976-1978.
    >> Share

  530. BENITEZ JC, Boucher ME, Dansin E, Kerjouan M, et al
    Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC.
    J Thorac Oncol. 2021;16:2144-2149.
    >> Share

  531. SCALERA S, Mazzotta M, Corleone G, Sperati F, et al
    KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    J Thorac Oncol. 2021;16:2065-2077.
    >> Share

  532. TEISHIKATA T, Shiraishi K, Shinno Y, Kobayashi Y, et al
    An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
    J Thorac Oncol. 2021;16:2133-2138.
    >> Share

  533. YANG Y, Sun J, Wang Z, Fang J, et al
    Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
    J Thorac Oncol. 2021;16:2109-2120.
    >> Share

    November 2021
  534. LEIGHL NB, Laurie SA, Goss GD, Hughes BGM, et al
    CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
    J Thorac Oncol. 2021 Nov 17. pii: S1556-0864(21)03322.
    >> Share

  535. ROLFO C, Meshulami N, Russo A, Krammer F, et al
    Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.
    J Thorac Oncol. 2021 Nov 10. pii: S1556-0864(21)03309.
    >> Share

  536. GOUNANT V, Ferre VM, Soussi G, Charpentier C, et al
    Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses.
    J Thorac Oncol. 2021 Nov 2. pii: S1556-0864(21)03286.
    >> Share

  537. STOCK-MARTINEAU S, Shepherd FA
    EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1793-1797.
    >> Share

  538. MOORE S, Wheatley-Price P
    EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1788-1792.
    >> Share

  539. YANG C, Li Y, Xiao SY
    Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?
    J Thorac Oncol. 2021;16:1785-1787.
    >> Share

  540. LOPEZ-CASTRO R, Recondo G, Gorria T, Mezquita L, et al
    A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1782-1784.
    >> Share

  541. ZHU VW, Ou SI
    Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
    J Thorac Oncol. 2021;16:1778-1781.
    >> Share

  542. ADJEI AA
    Tackling the High Cost of Oncology Drugs.
    J Thorac Oncol. 2021;16:1774-1777.
    >> Share

  543. DE BAERE T, Woodrum D, Tselikas L, Abtin F, et al
    The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up.
    J Thorac Oncol. 2021;16:1840-1849.
    >> Share

  544. MIKUBO M, Inoue Y, Liu G, Tsao MS, et al
    Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
    J Thorac Oncol. 2021;16:1798-1809.
    >> Share

  545. VAN DEN BROEK MFM, Levy S, Buikhuisen WA, Dijke K, et al
    Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
    J Thorac Oncol. 2021;16:1810-1820.
    >> Share

  546. CHIAPPETTA M, Lococo F, Zanfrini E, Moroni R, et al
    The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives.
    J Thorac Oncol. 2021;16:1936-1945.
    >> Share

  547. SAALFELD FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, et al
    Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    J Thorac Oncol. 2021;16:1952-1958.
    >> Share

  548. YEAP BY, De Rienzo A, Gill RR, Oster ME, et al
    Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1925-1935.
    >> Share

    October 2021
  549. PAZ-ARES LG, Ramalingam SS, Ciuleanu TE, Lee JS, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03207.
    >> Share

  550. MEZA R, Cao P, Jeon J, Taylor KL, et al
    Brief Report: Impact of joint lung cancer screening and cessation interventions under the new USPSTF recommendations.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03208.
    >> Share

  551. ROBBINS HA, Cheung LC, Chaturvedi AK, Baldwin DR, et al
    Management of lung cancer screening results based on individual prediction of current and future lung cancer risk.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03244.
    >> Share

  552. HUO KG, Notsuda H, Fang Z, Liu NF, et al
    Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03205.
    >> Share

  553. SONG Z, Lian S, Mak S, Chow MZ, et al
    Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
    J Thorac Oncol. 2021 Oct 6. pii: S1556-0864(21)03219.
    >> Share

  554. DZIADZIUSZKO R, Didkowska J, Jassem J
    Authors' Reply to Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e94-e95.
    >> Share

  555. ZATONSKI WA, Janik-Koncewicz K, Zatonski M
    Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e93-e94.
    >> Share

  556. OCAK S, Tournoy K, Berghmans T, Demedts I, et al
    Lung Cancer in Belgium.
    J Thorac Oncol. 2021;16:1610-1621.
    >> Share

  557. TSIM S, Alexander L, Kelly C, Shaw A, et al
    Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    J Thorac Oncol. 2021;16:1705-1717.
    >> Share

  558. DERKS JL, Rijnsburger N, Hermans BCM, Moonen L, et al
    Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice.
    J Thorac Oncol. 2021;16:1632-1646.
    >> Share

  559. LUO J, Beattie JA, Fuentes P, Rizvi H, et al
    Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:1759-1764.
    >> Share

  560. DENG C, Zheng Q, Zhang Y, Jin Y, et al
    Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations.
    J Thorac Oncol. 2021;16:1684-1693.
    >> Share

  561. MYRAND SP
    A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.
    J Thorac Oncol. 2021;16:e95.
    >> Share

  562. SUTEJA L, Yeong J, Tan AC, Toy W, et al
    Improving Precision and Implementation of Immuno-Oncology Biomarkers.
    J Thorac Oncol. 2021;16:e91-e93.
    >> Share

  563. YANG H, Hall SRR, Yao F
    Improving Prediction Marker Models With the Ratio of CD39+CD8+ to Total CD8+ T cells: How Good Is Good Enough?
    J Thorac Oncol. 2021;16:e88-e91.
    >> Share

  564. ZHAO H, Li J, Zhang Z, Zhang L, et al
    Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials".
    J Thorac Oncol. 2021;16:e87-e88.
    >> Share

  565. DAO QL, Phung Q, Liu MA
    Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials.
    J Thorac Oncol. 2021;16:e86-e87.
    >> Share

  566. FAN C, Zhao Q, Jiang Z, Xin T, et al
    Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?".
    J Thorac Oncol. 2021;16:e85.
    >> Share

  567. ZHENG MM, Li YS, Sun H, Chen HJ, et al
    Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases?
    J Thorac Oncol. 2021;16:e82-e84.
    >> Share

  568. LINDBERG K, Lax I, Karlsson K, Lewensohn R, et al
    In Response to Rosenberg et al. "The Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Window".
    J Thorac Oncol. 2021;16:e81-e82.
    >> Share

  569. ROSENBERG SA, Mak R, Kotecha R, Loo BW Jr, et al
    The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window.
    J Thorac Oncol. 2021;16:e79-e80.
    >> Share

  570. STIRLING RG
    Posttreatment Surveillance Challenges in the Era of Precision Medicine.
    J Thorac Oncol. 2021;16:e77-e78.
    >> Share

  571. ARIK Z, Erman M
    Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?
    J Thorac Oncol. 2021;16:e77.
    >> Share

  572. ZHANG JT, Wu YL
    Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021;16:1627-1631.
    >> Share

  573. ZHOU F, Zhou C
    Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021;16:1622-1626.
    >> Share

  574. MESCI A, Tsakiridis T, Swaminath A
    Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
    J Thorac Oncol. 2021;16:1607-1609.
    >> Share

  575. BOTTICELLA A, Levy A, Le Pechoux C
    Stage III NSCLC in Low- and Middle-Income Countries: Where Are We in 2021?
    J Thorac Oncol. 2021;16:1605-1606.
    >> Share

  576. NICHOLSON AG, Moreira AL, Mino-Kenudson M, Popat S, et al
    Grading in Lung Adenocarcinoma: Another New Normal.
    J Thorac Oncol. 2021;16:1601-1604.
    >> Share

  577. ROKUTAN-KURATA M, Yoshizawa A, Ueno K, Nakajima N, et al
    Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:1753-1758.
    >> Share

    September 2021
  578. SALEH MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, et al
    Comprehensive Analysis of TP53 and KEAP1 Mutations and their Impact on Survival in Localized and Advanced Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Sep 30. pii: S1556-0864(21)03187.
    >> Share

  579. QU S, Fetsch P, Thomas A, Pommier Y, et al
    Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers.
    J Thorac Oncol. 2021 Sep 14. pii: S1556-0864(21)03186.
    >> Share

  580. NISHINO M, Hatabu H, Ricciuti B, Vaz V, et al
    Brief Report Axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: Incidence, predisposing factors, and imaging characteristics.
    J Thorac Oncol. 2021 Sep 7. pii: S1556-0864(21)03184.
    >> Share

  581. BESTVINA CM, Pointer KB, Karrison T, Al-Hallaq H, et al
    A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study).
    J Thorac Oncol. 2021 Sep 6. pii: S1556-0864(21)02441.
    >> Share

  582. TRAN HTT, Nguyen S, Nguyen KK, Pham DX, et al
    Lung Cancer in Vietnam.
    J Thorac Oncol. 2021;16:1443-1448.
    >> Share

  583. SINGH AK, Sands JM
    Yet Another Reminder of the Value of Lung Cancer Screening.
    J Thorac Oncol. 2021;16:1437-1439.
    >> Share

  584. ZHAO H, Zhang Z, Zhang L
    Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e72-e76.
    >> Share

  585. YAMAOKA T, Kim YH, Iwatsubo S, Nishimura Y, et al
    The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e71-e72.
    >> Share

  586. BORZI C, Caiola E, Ganzinelli M, Centonze G, et al
    miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC.
    J Thorac Oncol. 2021;16:e68-e70.
    >> Share

  587. BI G, Liang J, Shan G, Zhan C, et al
    Some Thoughts Concerning the Mutational Background of Cell Lines and Heterogeneity of Bulk Tumor.
    J Thorac Oncol. 2021;16:e67-e68.
    >> Share

  588. LEE HY
    A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis.
    J Thorac Oncol. 2021;16:1440-1442.
    >> Share

  589. BIRONZO P, Passiglia F, Novello S
    Winds From the ORIENT: New Data to Inform RATIONAL Choice?
    J Thorac Oncol. 2021;16:1434-1436.
    >> Share

  590. UPRETY D, Remon J, Adjei AA
    All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC.
    J Thorac Oncol. 2021;16:1429-1433.
    >> Share

  591. LIAO BC, Chih-Hsin Yang J
    Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1426-1428.
    >> Share

  592. NAKASHIMA K, Tsubata Y, Niihara H, Araki A, et al
    Palm Pustules Induced by Pemetrexed.
    J Thorac Oncol. 2021;16:1589-1591.
    >> Share

  593. POZZESSERE C, Lazor R, Jumeau R, Peters S, et al
    Imaging Features of Pulmonary Immune-related Adverse Events.
    J Thorac Oncol. 2021;16:1449-1460.
    >> Share

  594. VANDENHOECK J, van Meerbeeck JP, Fransen E, Raskin J, et al
    DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:1461-1478.
    >> Share

    August 2021
  595. CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
    Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.
    J Thorac Oncol. 2021 Aug 30. pii: S1556-0864(21)02398.
    >> Share

  596. DOROSHOW DB, Wei W, Gupta S, Zugazagoitia J, et al
    PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02392.
    >> Share

  597. PLANCHARD D, Besse B, Groen HJM, Hashemi SMS, et al
    Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02403.
    >> Share

  598. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02401.
    >> Share

  599. KERPEL-FRONIUS A, Tammemagi M, Cavic M, Henschke C, et al
    Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02391.
    >> Share

  600. SHIRASAWA M, Yoshida T, Shimoda Y, Takayanagi D, et al
    Differential Immune-Related Microenvironment Determines PD-1/PD-L1 Blockade Efficacy in Advanced Non-Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02373.
    >> Share

  601. YAMAGUCHI H, Wakuda K, Fukuda M, Kenmotsu H, et al
    A phase II study of osimertinib for radiotherapy-naive CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02372.
    >> Share

  602. WALIANY S, Zhu H, Wakelee H, Padda SK, et al
    Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
    J Thorac Oncol. 2021 Aug 18. pii: S1556-0864(21)02377.
    >> Share

  603. QUAIFE SL, Dickson JL, Brain KE, Kurtidu C, et al
    Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study.
    J Thorac Oncol. 2021 Aug 14. pii: S1556-0864(21)02369.
    >> Share

  604. HERZOG BH, Devarakonda S, Govindan R
    Overcoming chemotherapy resistance in Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Aug 3. pii: S1556-0864(21)02333.
    >> Share

  605. AREDO JV, Wakelee HA, Han SS
    A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
    J Thorac Oncol. 2021;16:e59-e60.
    >> Share

  606. PELOSI G, Pasini F
    Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
    J Thorac Oncol. 2021;16:e57-e59.
    >> Share

  607. SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
    Lung Cancer in India.
    J Thorac Oncol. 2021;16:1250-1266.
    >> Share

  608. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:e63-e65.
    >> Share

  609. MLADKOVA N, Lo S, Brown PD, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: Interpreting the Evidence.
    J Thorac Oncol. 2021;16:e60-e63.
    >> Share

  610. COOPER WA, Lantuejoul S, Mino-Kenudson M
    Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC-Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?
    J Thorac Oncol. 2021;16:1247-1249.
    >> Share

  611. RUIZ J, Chan M, Strowd RE
    Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail.
    J Thorac Oncol. 2021;16:1244-1246.
    >> Share

  612. SMIT EF, Belderbos J
    Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?
    J Thorac Oncol. 2021;16:1242-1243.
    >> Share

  613. COLOMBO M, Ndembe G, Broggini M
    KRAS Targeting and Resistance: Anticipating the Expectable.
    J Thorac Oncol. 2021;16:1239-1241.
    >> Share

  614. HUDDAR P, Califano R
    Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue.
    J Thorac Oncol. 2021;16:1236-1238.
    >> Share

  615. SHAVERDIAN N, Offin M, Shepherd AF, Simone CB 2nd, et al
    The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
    J Thorac Oncol. 2021;16:1392-1402.
    >> Share

  616. FAN C, Zhao Q, Li L, Shen W, et al
    Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier:
    J Thorac Oncol. 2021;16:1359-1368.
    >> Share

  617. YEONG J, Suteja L, Simoni Y, Lau KW, et al
    Intratumoral CD39(+)CD8(+) T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.
    J Thorac Oncol. 2021;16:1349-1358.
    >> Share

  618. KOGA T, Suda K, Fujino T, Ohara S, et al
    KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    J Thorac Oncol. 2021;16:1321-1332.
    >> Share

  619. YOTSUKURA M, Asamura H, Motoi N, Kashima J, et al
    Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung.
    J Thorac Oncol. 2021;16:1312-1320.
    >> Share

  620. BORZI C, Ganzinelli M, Caiola E, Colombo M, et al
    LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
    J Thorac Oncol. 2021;16:1298-1311.
    >> Share

    July 2021
  621. DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
    Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
    >> Share

  622. PATEL SA, Herynk MH, Cascone T, Saigal B, et al
    Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
    >> Share

  623. SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
    IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
    >> Share

  624. SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
    Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
    J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
    >> Share

  625. STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
    Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
    J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
    >> Share

  626. JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
    Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
    >> Share

  627. AI X, Wang Q, Cheng Y, Liu X, et al
    Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
    >> Share

  628. POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
    Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
    >> Share

  629. MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
    High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
    >> Share

  630. WANG Y, Li J, Chang S, Dong Y, et al
    Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
    >> Share

  631. ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
    Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
    >> Share

  632. HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
    Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
    >> Share

  633. PARK HR, Kim TM, Lee Y, Kim S, et al
    Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
    >> Share

  634. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
    >> Share

  635. MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
    Lung Cancer in Greece.
    J Thorac Oncol. 2021;16:1058-1066.
    >> Share

  636. UGUEN A
    Each RET Break-Apart Fluorescence In Situ Hybridization Probe Requires Proper Interpretation Criteria.
    J Thorac Oncol. 2021;16:e55.
    >> Share

  637. ZHU VW, Zhang SS, Zhang J, Swensen J, et al
    Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.
    J Thorac Oncol. 2021;16:e51-e54.
    >> Share

  638. DOWLATI A, Chan T
    Pursuing Immunotherapeutic Targets in SCLC.
    J Thorac Oncol. 2021;16:1056-1057.
    >> Share

  639. GRANNIS FW JR
    Do Cancer Screening Researchers Have a Continuing Ethical Obligation to Their Study Subjects?
    J Thorac Oncol. 2021;16:1053-1055.
    >> Share


  640. Dr. Gouri Shankar Bhattacharyya, MD, PhD, FRCP: In Memoriam (October 31, 1958-May 1, 2021).
    J Thorac Oncol. 2021;16:1043-1044.
    >> Share

  641. LE-RADEMACHER J, Wang X
    Time-To-Event Data: An Overview and Analysis Considerations.
    J Thorac Oncol. 2021;16:1067-1074.
    >> Share

  642. GOODWIN D, Rathi V, Conron M, Wright GM, et al
    Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing.
    J Thorac Oncol. 2021;16:1166-1175.
    >> Share

  643. YANG SR, Chang JC, Leduc C, Tan KS, et al
    Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.
    J Thorac Oncol. 2021;16:1188-1199.
    >> Share

  644. LINDBERG K, Grozman V, Karlsson K, Lindberg S, et al
    The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
    J Thorac Oncol. 2021;16:1200-1210.
    >> Share

  645. HAN DH, Duan F, Wu Y, Goo JM, et al
    Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
    J Thorac Oncol. 2021;16:1118-1126.
    >> Share

    June 2021
  646. WARREN GW, Lim VS, Chowdhary M, Marwaha G, et al
    Brief Report: New Pulmonary Infiltrates Observed on Computed Tomography Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for COVID-19.
    J Thorac Oncol. 2021 Jun 21. pii: S1556-0864(21)02232.
    >> Share

  647. AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
    Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
    J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
    >> Share

  648. SU CC, Wu JT, Neal JW, Popat RA, et al
    Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
    >> Share

  649. ANG YLE, Chia PL, Chua KLM, Devanand A, et al
    Lung Cancer in Singapore.
    J Thorac Oncol. 2021;16:906-911.
    >> Share

  650. RAMI-PORTA R, Goldstraw P, Asamura H
    Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
    J Thorac Oncol. 2021;16:902-905.
    >> Share

  651. GRASS GD, Scott JG, Sedor G, Kattan MW, et al
    Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e48-e49.
    >> Share

  652. DU Y, Hu Z, Liang J, Zhan C, et al
    Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e47.
    >> Share

  653. RYAN BM
    In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e46.
    >> Share

  654. LIANG J, Hu Z, Zhan C, Wang Q, et al
    Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e45-e46.
    >> Share

  655. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
    J Thorac Oncol. 2021;16:e42-e45.
    >> Share

  656. BREEN WG, Brown PD, Laack NN
    Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
    J Thorac Oncol. 2021;16:e41-e42.
    >> Share

  657. DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
    Could Protons Promote Tumor Control by Avoiding Lymphopenia?
    J Thorac Oncol. 2021;16:e39-e41.
    >> Share

  658. BAUMAN J, Borghaei H
    To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:894-896.
    >> Share

  659. WARREN GW, Evans WK, Dresler C
    Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
    J Thorac Oncol. 2021;16:891-893.
    >> Share

  660. CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
    Crizotinib in Patients With MET-Amplified NSCLC.
    J Thorac Oncol. 2021;16:1017-1029.
    >> Share

  661. FINN SP, Addeo A, Dafni U, Thunnissen E, et al
    Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
    J Thorac Oncol. 2021;16:990-1002.
    >> Share

  662. STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
    Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
    J Thorac Oncol. 2021;16:960-967.
    >> Share

    May 2021
  663. JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
    Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
    J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
    >> Share

  664. ZHOU C, Wu L, Fan Y, Wang Z, et al
    Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
    >> Share

  665. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
    >> Share

  666. JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
    Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
    >> Share

  667. BARBI J, Patnaik SK, Pabla S, Zollo R, et al
    Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
    >> Share

  668. LU S, Wang J, Yu Y, Yu X, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
    >> Share

  669. ZHAO H, Yao W, Min X, Gu K, et al
    Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
    >> Share

  670. LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
    Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
    J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
    >> Share

  671. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
    J Thorac Oncol. 2021;16:e36-e37.
    >> Share

  672. PIRKER R, Prosch H, Popper H, Klepetko W, et al
    Lung Cancer in Austria.
    J Thorac Oncol. 2021;16:725-733.
    >> Share

  673. KIM CG, Cho BC, Lim SM
    Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    J Thorac Oncol. 2021;16:709-711.
    >> Share

  674. LI M, Zhan C, Wang Q
    Is the Story of M Descriptors Fulfilled or Finished?
    J Thorac Oncol. 2021;16:e36-e37.
    >> Share

  675. METOVIC J, Bianchi F, Barella M, Papotti M, et al
    SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
    J Thorac Oncol. 2021;16:e32-e35.
    >> Share

  676. DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
    Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:e31-e32.
    >> Share

  677. NISHIO M, Mendus D, Wang L, Socinski MA, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2021;16:e30-e31.
    >> Share

  678. DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
    IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
    J Thorac Oncol. 2021;16:e29-e30.
    >> Share

  679. SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
    Letter Response.
    J Thorac Oncol. 2021;16:e28-e29.
    >> Share

  680. MISTRY HB
    Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
    J Thorac Oncol. 2021;16:e27.
    >> Share

  681. RIMNER A, Wu AJ, Grills IS
    What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
    J Thorac Oncol. 2021;16:722-724.
    >> Share

  682. WESTEEL V
    Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
    J Thorac Oncol. 2021;16:719-721.
    >> Share

  683. JULOORI A, Vokes EE
    Beyond PACIFIC: Uncharted Waters.
    J Thorac Oncol. 2021;16:715-718.
    >> Share

  684. LIU SY, Wu YL
    Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
    J Thorac Oncol. 2021;16:712-714.
    >> Share

  685. ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
    Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
    J Thorac Oncol. 2021;16:706-708.
    >> Share

  686. MATSUI S, Le-Rademacher J, Mandrekar SJ
    Statistical Models in Clinical Studies.
    J Thorac Oncol. 2021;16:734-739.
    >> Share

  687. STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
    Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:784-797.
    >> Share

  688. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:840-849.
    >> Share

  689. HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
    Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
    J Thorac Oncol. 2021;16:868-872.
    >> Share

  690. FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
    J Thorac Oncol. 2021;16:860-867.
    >> Share

  691. NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
    Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2021;16:740-763.
    >> Share

  692. PASSARO A, Mok T, Peters S, Popat S, et al
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
    J Thorac Oncol. 2021;16:764-773.
    >> Share

    April 2021
  693. AI X, Pan Y, Shi J, Yang N, et al
    Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
    >> Share

  694. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
    >> Share

  695. HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
    Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
    >> Share

  696. QIAO M, Jiang T, Liu X, Mao S, et al
    Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
    >> Share

  697. ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
    Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
    J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
    >> Share

  698. SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
    Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
    >> Share

  699. PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
    Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
    J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
    >> Share

  700. BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
    Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
    J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
    >> Share

  701. MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
    Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
    >> Share

  702. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
    >> Share

  703. ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
    SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
    >> Share

  704. LIU L, Bai H, Wang C, Seery S, et al
    Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
    >> Share

  705. ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
    Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
    >> Share

  706. THOMAS PL, Groves SM, Zhang YK, Li J, et al
    Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
    >> Share

  707. JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
    Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
    J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
    >> Share

  708. GOTO T
    Lymph Node Dissection for NSCLC at Whose Discretion?
    J Thorac Oncol. 2021;16:e25.
    >> Share

  709. PAZ-ARES L
    Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e24.
    >> Share

  710. XU J, Nie H, Wan H
    Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e23-e24.
    >> Share

  711. QIU H, Li Q, Xiao Y, Wu D, et al
    A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
    J Thorac Oncol. 2021;16:e21-e23.
    >> Share

  712. NAGASAKA M, Ou SI
    Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2021;16:532-536.
    >> Share

  713. CAMIDGE DR
    Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
    J Thorac Oncol. 2021;16:528-531.
    >> Share

  714. GADGEEL SM
    Patient-Reported Outcomes in the Era of Immunotherapy Trials.
    J Thorac Oncol. 2021;16:516-518.
    >> Share

  715. FALKSON CB
    Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
    J Thorac Oncol. 2021;16:515.
    >> Share

  716. PATEL SP, Kelly K
    IMpower 132: Loses Power at the Finish Line.
    J Thorac Oncol. 2021;16:512-514.
    >> Share

  717. PACHECO JM, Schenk EL
    CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2021;16:509-511.
    >> Share

  718. SEBASTIAN M, Stratmann JA, Eberhardt WEE
    Too Good to be True?
    J Thorac Oncol. 2021;16:507-508.
    >> Share

  719. LE X
    Heterogeneity in MET-Aberrant NSCLC.
    J Thorac Oncol. 2021;16:504-506.
    >> Share

  720. OU FS, Michiels S, Shyr Y, Adjei AA, et al
    Biomarker Discovery and Validation: Statistical Considerations.
    J Thorac Oncol. 2021;16:537-545.
    >> Share

  721. TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
    Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
    J Thorac Oncol. 2021;16:677-685.
    >> Share

  722. LE X, Negrao MV, Reuben A, Federico L, et al
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
    J Thorac Oncol. 2021;16:583-600.
    >> Share

  723. LAM VK, Zhang J, Wu CC, Tran HT, et al
    Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
    J Thorac Oncol. 2021;16:601-609.
    >> Share

  724. VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
    Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
    J Thorac Oncol. 2021;16:619-629.
    >> Share

  725. MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
    Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
    J Thorac Oncol. 2021;16:610-618.
    >> Share

    March 2021
  726. SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
    First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
    J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
    >> Share

  727. DY GK, Prasad D, Kumar P, Attwood K, et al
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
    J Thorac Oncol. 2021;16:e19-e20.
    >> Share

  728. YANG X, Li Y, Duan Q, Zhang Q, et al
    Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
    J Thorac Oncol. 2021;16:e17-e19.
    >> Share

  729. SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
    Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2021;16:e15-e17.
    >> Share

  730. UPRETY D
    Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
    J Thorac Oncol. 2021;16:371-374.
    >> Share

  731. REMON J, Hendriks LEL
    Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:368-370.
    >> Share

  732. ADJEI AA
    Controversies in Thoracic Oncology.
    J Thorac Oncol. 2021;16:366-367.
    >> Share

  733. RAJAN A
    Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
    J Thorac Oncol. 2021;16:352-354.
    >> Share

  734. SONG L, Xu Q, Lizaso A, Zhang Y, et al
    Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:349-351.
    >> Share

  735. SONG Z, Lu C, Xu CW, Zheng Z, et al
    Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
    J Thorac Oncol. 2021;16:344-348.
    >> Share

  736. WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
    Statistical Considerations for Subgroup Analyses.
    J Thorac Oncol. 2021;16:375-380.
    >> Share

  737. NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
    Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
    J Thorac Oncol. 2021;16:439-451.
    >> Share

  738. NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
    Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
    J Thorac Oncol. 2021;16:486-491.
    >> Share

  739. LI W, Guo L, Liu Y, Dong L, et al
    Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    J Thorac Oncol. 2021;16:404-418.
    >> Share

  740. GIACCONE G, Kim C
    Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
    J Thorac Oncol. 2021;16:483-485.
    >> Share

  741. SECHI E, Zekeridou A
    Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    J Thorac Oncol. 2021;16:381-394.
    >> Share

    February 2021
  742. LEE J, Ahn MJ
    A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e14.
    >> Share

  743. ZHENG MM, Li YS, Sun H, Wu YL, et al
    Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e12-e14.
    >> Share

  744. TSUI DCC, Camidge DR
    Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
    J Thorac Oncol. 2021;16:194-196.
    >> Share

  745. SEQUIST LV, Skates SJ, Haas W
    A New Era of Protein-Based Assays for Cancer Early Detection.
    J Thorac Oncol. 2021;16:191-193.
    >> Share

  746. FERRARA R, Campochiaro C, Garassino MC
    Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:183-186.
    >> Share

  747. PADDA SK, Reckamp KL
    Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
    J Thorac Oncol. 2021;16:178-182.
    >> Share

  748. MOK T, Peters S, Camidge DR, Noe J, et al
    Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
    J Thorac Oncol. 2021;16:259-268.
    >> Share

  749. LI B, Zhang Y, Miao L, Ma L, et al
    Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
    J Thorac Oncol. 2021;16:310-317.
    >> Share

  750. BANFILL K, Giuliani M, Aznar M, Franks K, et al
    Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
    J Thorac Oncol. 2021;16:216-227.
    >> Share

  751. GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
    Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
    J Thorac Oncol. 2021;16:269-277.
    >> Share

  752. PETERS S, Felip E, Dafni U, Tufman A, et al
    Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
    J Thorac Oncol. 2021;16:278-288.
    >> Share

  753. JIANG T, Fang Z, Tang S, Cheng R, et al
    Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:237-249.
    >> Share

  754. OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
    Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
    J Thorac Oncol. 2021;16:228-236.
    >> Share

  755. LE X, Nilsson M, Goldman J, Reck M, et al
    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:205-215.
    >> Share

  756. MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
    Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
    J Thorac Oncol. 2021;16:318-326.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016